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The peptide assembly mechanism is important for development of both functional 
biomaterials and clinical therapies. Although the assembly structures and assembling 
pathways have been studied for decades, the mechanism remains to be clarified, as the 
assembly pathway is a complex multistep process with various assembly morphologies 
and structures. 
 The main goal of this thesis is to investigate the assembly mechanism of 
functional peptide assemblies. The crucial building blocks capable of assembly are 
synthesized and selected via the dynamic combinatorial networks (DCNs), which yield 
sequence-defined oligomer with high fidelity. Both experimental analyses and 
mathematic modeling are applied to confirm the interplay between the chemical 
distribution and emergent physical transitions in the networks; model discrimination 
shows that the chemical nature of the DCNs is affected and shifted at different physical 
stage. 
 Next, to simulate the two-step nucleation process observed in the DCNs, a peptide 
assembly model is developed with two-step nucleation. The model simulates the phase 
transitions between different physical phases, given combinations of the Flory-Huggins 
parameter, the particle growth constant, and the binding energy to assemblies. The final 
physical phase distribution is determined by the solubility of the particle and assembly 
phases, where the phase with the lower solubility accumulates. To explore the potential 
of this model, experimental results from the peptide, Ac-KLVFFAE-NH2, is rationally 
explained by this model. The model is then extended for a polydisperse system, where the 
 xxii
peptides undergo oligomerization, to simulate the chemical and physical transitions in the 
DCNs. The polydisperse model shows that the physical and chemical distribution may 
reach the steady state independently. 
 The assembly pathway with two-step nucleation is experimentally investigated 
with the pH sensitive A(16-22) peptide, which assembles into fiber at neutral pH but 
tubes at acidic pH. The difference between the nucleation and propagation environments 
for the two-step nucleation mechanism affects the assembly kinetics and morphological 
selection. Although A(16-22) assembles into ribbons pH-independently, the ribbon 
intermediates undergo pH-dependent reaction pathway and transition into different 
morphologies under different pH conditions.  
 Finally, the catalytic peptide assemblies are analyzed. The methodol substrate is 
cleaved by Ac-KLVFFAL-NH2 and Ac-OrnLVFFAL-NH2 nanotubes enantioselectively. 
The Experimental results are analyzed with a modified Michaelis-Menten mechanism to 
resolve the nature of this catalytic system, including the number of peptides per binding 
site, the enantioselectivity, and the stability of the tubes. The simulations suggest similar 
binding pocket size for the both nanotubes, and the assemblies are stable throughout the 
entire reaction time. The enantioselectivity for the R- and S-methodol substrate may 
come from the chemical selectivity of the peptide nanotubes, but not from the difference 
of the binding affinity, based on the analysis.  
 The results from this thesis provide a comprehensive investigation of the 
construction of functional peptide assemblies. The building block synthesis and selection, 
 xxiii
the assembly structure and mechanism, and the functional properties of the peptide 
assemblies are reported and discussed. 
 1 
CHAPTER 1. INTRODUCTION 
1.1 Amyloid Peptide Assembly 
Amyloid structures are highly ordered aggregates formed by assembled peptides or 
proteins, and they have triggered intense interest as they cause the neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s diseases [1-5]. The design of new therapies 
against these diseases depends on the understanding of the structures and the aggregation 
mechanism of both the amyloid intermediates [3, 6-9] and final products [10, 11]. Other 
than clinical therapies, the amyloid assemblies have also been applied for the 
construction of functional nanomaterials, which may be used for drug delivery [12-15], 
nanofabrication [16, 17], and biocatalysts [18]. In the following sections, the amyloid-
related diseases, the functional peptide-assemblies, and the techniques characterizing and 
quantifying the assemblies will be discussed.  
1.1.1 Peptide Amyloid-related Diseases 
The assembly and aggregation of peptides and proteins have caused many fatal diseases 
such as neurodegenerative diseases, type 2 diabetes, and prion diseases. For the 
neurodegenerative disease, such as Alzheimer’s disease, the patients may undergo 
progressive dementia or decline in memory and cognitive functions. One of the peptides 
causing these diseases is the -amyloid (A) peptide, which is the cleavage product of 
the amyloid precursor protein. The accumulation of extracellular A plaques is found in  
patient’s brain, and the deposit of the plaques is necessary but not sufficient to cause the 
disease [19]. There are other amyloid assemblies of peptides/proteins neuropathologically 
 2 
related to diseases. The aggregation of -synuclein [20] is related to Parkinson’s disease, 
which cause movement disorder and gait disturbance. To efficiently develop the clinical 
therapies for these diseases, it is important to understand the assembly mechanism of the 
peptides and proteins. 
1.1.2 Functional Peptide Self-assemblies 
Peptide assembly has become a powerful methodology to construct functional nanoscale 
materials. The morphology and function of the peptide assemblies may be manipulated at 
the molecular level by varying the sequence of the peptides. Through sequence 
modification, the structure-function relationships between different peptides may be 
studied systematically, which accelerates the development of functional peptide-based 
architectures. Also, some peptide assemblies are sensitive to external stimuli such as pH 
[21], temperature [21], and light [22], and these stimuli may be applied to diversify the 
structures and thus the functionalities of the peptide assemblies. In the following 
paragraphs, several functional peptide assembly-based materials are discussed.  
 Excellent catalytic activity [23] and selectivity [24] of protein enzymes have 
inspired scientists to synthesize catalysts with amino acids as the basic building blocks. 
The catalytic efficiency of protein enzymes relies on their structures, which are essential 
for substrate recognition, size of the binding pocket, and the catalytic pathway. However, 
the complex protein folding mechanism has become a problem for artificial enzyme 
development, as the enzymes need to fold properly for catalytic functions [25, 26]. On 
the other hand, without the needs to solve the complex protein folding mechanism, 
peptide assembly has shown promising potential as biocatalysts with a bottom-up 
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fabrication mechanism. As one of the first examples for catalytic peptide assemblies, 
Guler and coworkers assembled peptide amphiphile nanostructures able to break ester 
bonds [27]. Peptides with histidine residues as the catalytically reactive group were 
designed, and the peptide reacted similar to a Michaelis-Menten enzyme after they 
assembled into nanotubes. Other peptide-based assemblies have also shown catalytic 
ability for aldol reactions [28], hydrolysis [29], and Diels-Alder reaction with metal ions 
as the cofactors [30].  
 Other than the chemical function, peptide assemblies have been used as templates 
for nanofabrication. The peptide assemblies with well-defined shapes and sizes show 
remarkable capability to synthesize inorganic functional nanomaterials [17]. Silver 
nanowires have been successfully fabricated with reduction of ionic silver inside the 
peptide nanotubes, which are degraded with enzymes [16]. The amine groups at the 
assembly surface may also serve as nucleation sites to fabricate metal nanoparticles [31, 
32].  
 Compared to other organic materials, peptide assemblies are more suitable for 
drug delivery due to their biocompatibility, biodegradability, and multifunctionality [14, 
15]. Both hydrophobic and hydrophilic drugs may be carried with peptide assemblies as 
the vesicles [33-35], and the adjustable assembly structures given the tailorable sequences 
also make peptide assemblies efficient carriers to different target sites [36-38]. Other 
advantages, including high efficiency for drug loading, low ratio for drug lose, and high 
stability [39], also makes the nanostructures of assembled peptides excellent drug carriers 
over the other candidates at the nanoscale.  
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1.1.3 Morphologies and Structures of Peptide Assemblies 
The tailorable sequences of peptides make it possible to design and explore new 
structures and morphologies of the peptide assemblies. With different amino acid 
sequences, peptides assemble into diversified morphologies, such as tubes [40], sheets 
[41], vesicles [42], particles [21], and ribbons [43]. Common interactions driving peptide 
assembly are typically noncovalent, including hydrophobic interactions [44], electrostatic 
attraction [45], van der Waals interactions [46], – stacking [47], and hydrogen bonding 
[48]. The patterns of hydrogen bonding determine the secondary structure of the 
assembly; the assemblies possess -helix structure with intramolecular hydrogen bonds 
or -sheet structure with intermolecular hydrogen bonds. All of these morphologies and 
structures may be probed with appropriate instruments.  
1.1.4 Measuring the Kinetics and Structural Change of Peptide Assemblies 
Characterization and quantification of the peptide assemblies can be done with 
spectroscopic methods investigating the chemical, physical, and electrical properties of 
the assemblies. For example, peptide assemblies interact with clockwise- and 
counterclockwise-spinning light differently due to the chirality of the assemblies, which 
is affected by the secondary structure of the assemblies. The chirality generates a non-
zero circular dichroism (CD) signal [49], and thus CD spectroscopy provides reliable 
information to determine of the secondary structures of peptide assemblies [50] and to 
quantify the assembled peptides [51].  
 To probe the complex pathways and registries of the peptide assemblies with 
sufficient time resolution, FTIR has become a useful technique to address the peptide 
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assembly kinetics [45, 52]. FTIR is sensitive to the secondary structure of amyloid 
aggregation. The amide I bond from the antiparallel β-sheet structure shows one band 
around 1625 cm-1 and another around 1690 cm-1 on the IR spectrum. For parallel β-sheet 
structure, the amide I bond shows only one band around 1635 cm-1 [53-57]. More detailed 
structural information can be obtained with isotope-edited peptides, which provide 
structural information at the amino acid level [52, 58, 59]. The assemblies of 13C-
enriched peptides show IR spectra with split amide I bands; the 13C band is red shifted to 
smaller wavenumbers and is separated from the 12C band as a result. The separated bands 
allow specific determination of the coupling registries and the structural transitions of the 
assemblies [45, 60]. Also, the small mass requirement and rapid data acquisition make 
FTIR useful for measuring the kinetics of amyloid formation and maturation [52, 61]. 
 The fluorescence dye is another tool related to peptide assembly investigation. 
Fluorescence dyes are used to quantify the concentration of assembled peptides or 
proteins with -sheet amyloid structures. Congo Red (CR) shows a distinct apple-green 
birefringence upon binding to amyloid structure and thus serves as an indicator of 
amyloid assemblies. Thioflavin T (ThT) is another quantitative probe for peptide 
assemblies with cross -sheet structure, which fluoresces on binding. The high 
sensitivity, simplicity, and fast measurement make ThT an universal diagnostic for 
peptide assemblies [62]. 
 Finally, microscopy has been used to observe the morphology of the assemblies. 
Multiple imaging microscopies have been used to visualize the amyloid nanostructures, 
such as transmission electron microscopy (TEM), atomic force microscopy (AFM), 
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scanning electron microscopy (SEM), and fluorescence microscopy [63], which provide 
the morphological information with high resolution. 
1.1.5 Modeling the Mechanism and Kinetics of Peptide Self-assembly 
The range of peptide and protein sequences involved in amyloid assembly has 
complicated defining the assembly pathways and modeling, particularly the critical 
nucleation step [64]. One-step nucleation (1SN) [65-68] is the most direct model for 
assembly nucleation, which assumes that the free peptide monomers nucleate into 
ordered structures in solution. However, strong desolvation energy barriers are known to 
prevent assemblies from nucleating directly in solution [69, 70]. Instead, according to 
Ostwald’s rule of stages [71], the peptides may form a metastable phase prior to 
nucleation of fibers [72]. This two-step nucleation (2SN) has been observed widely not 
only in peptide amyloid assemblies [73-77], but also in the crystallization of proteins [70, 
78-83], colloids [84-86], minerals [87, 88] and polymers [89]. The morphologies of the 
metastable phases range from molecular clusters to macroscopic dense solution phases 
[90], which may either a) be incorporated as the assembly phases develop [21, 69, 79], b) 
coexist with the assembly phases [21, 78, 91], or c) dominate if assembly nucleation is 
slow or thermodynamically disfavored [11, 21, 72, 92].  
 Both 1SN and 2SN have been experimentally observed [75] and mathematically 
analyzed for peptide assembly. Several models describe 1SN nucleation occurring in 
solution directly [65-68, 93, 94], while 2SN requires an intermediate metastable phase to 
initiate the assembly phase. Pan and coworkers have simulated two-step nucleation of 
proteins with a phenomenological kinetic model as a function of temperature [95]. The 
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reversible formation of the metastable phase and irreversible nucleation of the assembly 
phase are assumed to be Arrhenius-type. They conclude that the rate-determining step of 
the assembly phase is assembly nucleation, which is controlled by both viscosity and 
monomer concentration in the metastable phase. Since the amount of the metastable 
phase significantly impacts the maturation of the assembly phase [96], Kashchiev and 
coworkers simulate the assembly nucleation rate as a function of the individual 
metastable particle size [97]. Later Auer et al. compare the difference between 1SN and 
2SN [72] using classical nucleation theory to simulate the formation of the metastable 
phases. However, all these efforts focus solely on assembly nucleation rate without 
including assembly maturation or monomer depletion. To explain protein crystallization 
data, Sauter and coworkers in 2015 proposed a 2SN kinetic model [90] that included the 
formation of a metastable phase, monomer depletion, and transition to the assembly 
phase. However, the model used the total peptide concentration to describe the metastable 
phase because of its poorly defined morphology. For peptide assembly, the peptide 
particle is a common metastable phase, and the individual size of the metastable particles 
or droplets are critically tied to nucleation rate with assemblies; the assemblies inside a 
particular particle do not extend into the solution phase until they become longer than that 
particular particle size.  
 After the assembly nucleated and is exposed into the solution, they propagate 
through consuming the other free peptides. In some models the assembly growth is 
assumed to be irreversible due to the stable assembly structures. Finke and Watzky 
proposed a pseudoelementary model [66] to describe the kinetics of peptide assembly. 
With a first order reaction for assembly nucleation and a second order reaction for 
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assembly autocatalytic growth, the model is able to describe the aggregation of several 
proteins and peptides, including -synuclein, amyloid  peptide, and polyglutamine. 
However, when the assembly dissolution is significant and thus the assembly growth is 
reversible, the peptides may dissociate from the end of the assemblies [68]. In addition, 
when mechanical forces are applied to the peptide solution by stirring or shacking, the 
assemblies will break in the middle and thus the number of active ends increase [67, 98], 
which accelerates the autocatalytic assembly kinetics [65, 68].  
1.2 Dynamic Combinatorial Networks 
In addition to assembling the peptides through non-covalent bonding, researchers have 
applied covalently interacting molecules to build a system with emergent functionality. In 
dynamic combinatorial networks (DCNs), the chemical complexity of the networks is 
achieved with reversible covalent linkages between different building blocks, and the 
composition of the networks is thermodynamically determined [99, 100]. Species, 
including the assemblies, in these complex networks are sensitive to the surroundings; 
they respond to external stimuli, and thus may be manipulated for different functions. 
This multicomponent assembly network may also shed a light on the origin of life, due to 
its environmental sensitivity and accumulating complexity [98].  
1.2.1 Reversible Linkages in Dynamic Combinatorial Networks 
The properties of the DCN may be determined with different reversible linkages and the 
building blocks. The dynamic combinatorial chemistry is different from the traditional 
combinatorial chemistry because of its reversible linkages [101], through which the 
distribution between different network members can change. Many reversible linkages 
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have been used to construct dynamic combinatorial networks, including the imine 
linkages [102] and the acetal linkages [103, 104].  
 The first imine-based dynamic combinatorial network was constructed to 
polymerize DNA [102], where the trimers reversibly make hexamers. Later the imine 
linkages have been applied to mediate the networks of aldehydes, amines, and 
macrocyclic molecules [105-108]. However, due to its high vulnerability to hydrolysis, 
these imine-based species are difficult to analyze with HPLC in aqueous solution, which 
is a common tool to separate and quantify the species in the DCNs. One solution for this 
problem is to incubate the network in water-free conditions [109].   
 For reversible acetal linkages, acid-catalyzed cyclic products may be produced 
with under thermodynamic control. The condensation of glycerol with isobutyraldehyde 
results in both five-membered ring and six-membered ring compounds (Figure 1.1) [110]. 
In this network, the five-membered ring product is kinetically favored, while the six-
membered ring product is more thermodynamically stable. The reversible nature of the 
acetal linkages gradually shifts the five-membered rings into the six-membered rings, and 
the later predominate in the end. Acetal linkages have also been applied to construct 
DCNs of diaminobutanediols [103, 111], benzene hexathiol with p-tolualdehyde [112], 
and pyrazolotriazone with aldehydes [113].  
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Figure 1.1  The condensation of glycerol with isobutyraldehyde under acidic 
conditions [110]. 
1.2.2 Self-templating and Assembly in Dynamic Combinatorial Networks 
Coupling peptide assembly and chemical transformation (peptide oligomerization) in 
DCNs opens a new door for materials with new structures and functions. In biological 
systems, replication of biopolymers is usually template-directed. This inspired 
researchers to amplify the members in the networks with assemblies as the templates; the 
members bind to the template to copy themselves, and the equilibrium is driven by the 
affinity between the templates and the members [114].  
 For peptide assemblies, the ends of the -sheet amyloid structure may be used to 
template the formation of the assembly building blocks. Ashkenasy and coworkers ligate 
the shorter peptide pieces into the full-length building blocks, which then assemble with 
their templates and elongate the assemblies (Figure 1.2) [115]. As shown in Figure 1.2, 
the precursors E and N are non-covalently bound to the end of the -sheet structure for 
ligation. The ligated E and N become the building block 1 and assemble into the -sheet 
structure. Later, Otto and coworkers report self-templating peptide-based macrocycles 
emerging from a DCN [98], whose hexamers and heptamers assemble into fibers. Their 
fiber assemblies possess -sheet structure, and are sensitive to external stimuli such as 
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shearing force. When mechanical force is applied, formation of hexamer and heptamer 
assemblies is accelerated, which consume the other members in the network through the 
templating effect.  
 
Figure 1.2  Formation of the building block in a peptide assembly system via self-
templating [115]. After the precursors, N and E, are bound to the end of the 
assembly of molecule 1, they are templated into molecule 1 with a covalent bond. 
 
1.2.3 Functional Dynamic Combinatorial Networks 
The reversible and flexible distribution of DCNs makes the networks an attractive tool to 
find ligands for biomolecular and synthetic receptors for drug discovery [116, 117]. The 
external targets serve as a template and amplify the desired members in the network. The 
interaction between the desired members and the targets becomes a “sink,” which drives 
the equilibrium to the desired member [118]. This strategy makes DCN effective in 
screening not only useful ligands and receptors for different targets, but also catalysts for 
different reactions. The efficiency of a catalyst depends on its selectivity for the substrate 
and chemical activity to catalyze the reaction. Several approaches have been made to 















selectivity to the target substrates [119, 120]. Catalytic members have been screened in 
this way for reactions like the Diels—Alder reaction [121] and the acetal hydrolysis 
reaction [122].  
1.3 Objectives 
The main goal of this thesis is to study the kinetic of peptide assembly with emergent 
functions (Figure 1.3). First of all, peptide oligomers capable of assembly are covalently 
synthesized via DCNs (the 1st dimension in Figure 1.3). Next, the kinetics of peptide 
assembly are mathematically and experimentally studied to understand the reaction 
pathway and the resulting morphologies (the 2nd dimension in Figure 1.3). Finally, the 
emergent catalytic function of the peptide assemblies is analyzed (the 3rd dimension in 
Figure 1.3). With the following chapters, the construction and the properties of the 
functional peptide assemblies are demonstrated.  
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Figure 1.3 －  The construction of peptide assembly with emergent catalytic 
function.  
 In chapter 2, the kinetics of DCNs are experimentally analyzed and 
mathematically modeled, which are constructed with chemically modified NF and NFF 
peptides. The network distribution is affected by both the chemical property of the 
building blocks and the emergent physical phases. The observed assemblies help to 
template the formation of peptide oligomers, which yields sequence-defined oligomers 
with high fidelity.  
 In chapter 3, a model is constructed to describe the peptide assembly process with 
two-step nucleation. This model simulates the formation of peptide fibers via the 
metastable particles. First, a monodisperse model addresses that both the solubility of 
peptide particle and assembly determines the final state of the system, while the process 
may be kinetically limited by slow particle growth/dissolution. This monodisperse model 
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is supported with the assembly kinetics of a model peptide, A(16-22), which are 
rationally explained by the model prediction. Finally, to simulate the transitions in the 
DCNs, the model is modified for a polydisperse system, and it shows that the steady state 
of the physical phase distribution and the chemical oligomer concentration distribution 
may be independent on each other. 
 In chapter 4, the pH-sensitive A(16-22) assembly is further examined. A(16-
22) assembly follows the two-step nucleation, and the fibers nucleate in the particles 
while grow in the solution. This environmental difference is important for the assembly 
stability and morphological selection. Here A(16-22) is incubated at both neutral and 
acidic pH to probe the structural evolution and the possible different reaction pathway.  
 In chapter 5, the catalytic function of the peptide assemblies is tested. The 
methodol substrate undergoes retro-aldol reaction with the peptide assemblies, and the 
experimental results are mathematically analyzed to clarify the reaction mechanism, size 
of the binding pocket, and the substrate selectivity. 
 Chapter 6 contains the summary of this work and the recommendation for future 




CHAPTER 2.  
KINETICS AND PHASE TRANSITIONS OF THE DYNAMIC 
COMBINATORIAL NETWORKS 
2.1 Introduction 
The natural sequence-defined biopolymers, such as enzymes or antibodies, have shown 
remarkable functions. Template-assisted polymerization is common and fundamental in 
natural biological systems to synthesize sequence-defined biopolymers, which usually 
requires catalytic enzymes to drive the reactions, such as DNA replication or protein 
translation. The necessity of catalytic enzymes complicates those polymer syntheses due 
to the complex interactions between the substrates and the enzymes. Hence, researchers 
seek for simpler strategies to synthesize and engineer the sequence-defined polymers for 
functional materials [123]. However, in several approaches the chain length distribution 
[124] and the sequence fidelity [125] of the polymers are hard to control. Here, the 
peptide-based dynamic combinatorial networks (DCNs) are constructed and reported, 
which show the ability to synthesize monodisperse biopolymers with high fidelity 
without enzymes. Two networks with reversible acetal linkages are discussed here: NF-
CHO and NFF-CHO networks. Both experimental techniques and mathematical 
modeling are combined to reveal the chemical and physical properties of the networks. 
The design of DCNs provides a simpler pathway to generate monodisperse peptide-based 
polymers, and opens a new way for functional biopolymer synthesis. 
2.2 Results and Discussion 
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2.2.1 Kinetics of the NF-CHO Network 
A DCN is generated with the NF-CHO monomer. The NF dipeptide is synthesized with 
standard Boc-peptide synthesis, with the C-terminus reduced to an aldehyde group. The 
Boc group (tert-Butyloxycarbonyl group) on this NF-CHO monomer is removed with 
trifluoroacetic acid (TFA) to activate the monomer, which then may perform 
polymerization and generate the network via the reversible acetal linkages (Figure 2.1).  
 
Figure 2.1 – Polymerization of the NF-CHO monomers. Image adapted from Ref. 
[126] with permission. 
 The NF-CHO network is incubated in 40% acetonitrile (ACN) aqueous solution 
with an initial monomer concentration of 8 mM, and the network species are identified by 
mass spectrometry (MS) after HPLC separation. Figure 2.2 shows the HPLC analysis of 
the NF-CHO network after two days of incubation. The mobile phase of HPLC (gradient 
ACN/water) stabilizes the species with quasi-neutral pH, under which the hydrolysis of 
the acetal linkages is limited [127]. The HPLC peaks have good Gaussian shapes, which 
suggest that the network species are stable during the HPLC separation without 
significant hydrolysis. As shown in Figure 2.2, there are five major products in the 
network identified: monomer, linear dimer, cyclic dimer, linear trimer, and cyclic trimer.  
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Figure 2.2 – The HPLC spectrum of the NF-CHO network after 2 days of 
incubation. Image adapted from Ref. [126] with permission. 
 To verify the reaction pathway, a model is constructed to describe the evolution of 
the network species with time. HPLC and MS sampling provide time-dependent changes 
over the initial 48 hr of NF-CHO network maturation, based on which a kinetic model 
(Figure 2.3) is constructed. M, D, Dc, T, Tc stand for monomer, linear dimer, cyclic dimer, 
linear trimer and cyclic trimer, respectively, in Figure 2.3. The model describes the 
polymerization (forward reaction) with forward rate constants (k1, k3, k5 and k7), while the 
backward rate constants are calculated based on the ratio of the forward rate constants 
and the corresponding equilibrium constants (K2, K4, K6, and K8).  
 
Figure 2.3 – Kinetic steps for the NF-CHO network in Figure 2.2. M, D, DC, T and 
TC represent monomer, linear dimer, cyclic dimer, linear trimer and cyclic trimer, 
respectively. k1, k3, k5, and k7 are the forward rate constants and K2, K4, K6, and K8 
are the corresponding equilibrium constants. 
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 The fit of the kinetic model in Figure 2.3 to the NF-CHO network concentrations 
(Figure 2.4a) follows the consumption of monomer up to 12 hours. The calculated curve 
then underestimates the monomer concentration at 19 hours but overestimates the 24-
hour data point. There is also a distinct concentration change for the linear dimer and 
trimer between 19 and 24 hours as highlighted in Figure 2.4b, which is not captured by 
the calculated curves. The deviation suggests that a physcial phase transition happens as 
the network matures, which changes the equilibrium between the species. This physical 
transition is probed with transmission electron microscope (TEM); as shown in Figure 
2.5, the particle phase emerges after 17 hr of incubation, and it is correlated with the 
deviation between the calculated and experimental data.  
 
Figure 2.4 – Fit of the NF-CHO network concentrations to the model in Figure 2.3. 
(a) Solid lines are fit using Figure 2.3 to the data. (b) Expansion of the y-axis in the 
left panel highlights a distinct transition between 19 hr and 24 hr.  
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Figure 2.5 – TEM images of the NF-CHO network after (a) 4 hr, (b) 17 hr, (c) 48 hr, 
and (d) 96 hr of incubation. Image adapted from Ref. [126] with permission. Scale 
bar = 100 nm. 
 The distinct changes in the physical state of the network in Figure 2.4 suggest that 
a single set of parameters is not sufficient to adequately describe the maturation of the 
network. Thus, the model is expanded into a two-stage model with a boundary at 21.5 
hours, halfway between the data points at 19 and 24 hours. This boundary separates the 
solution stage from the particle stage, which share common reactions but individually 
have unique rate and equilibrium constants. This two-stage model better describes the 
evolution of the NF-CHO DCN and covers the dimer and trimer formation with the 
emergent particle stage. Although both intramolecular (cyclization) and intermolecular 
(oligomerization) reactions occur actively in the solution stage, cyclization appears 
inaccessible in the particle stage. Amyloid peptide particles are desolvated and favor 
condensation, which should promote further polymerization between the species. 
However, the constant concentration of the cyclic dimers in the particle stage suggests 




Figure 2.6 – Fit of the NF-CHO concentrations to a two-stage model. The boundary 
at 21.5 hours defines the transition between the solution stage and the particle stage. 
 To more rigorously evaluate these models and the potential of over-fitting with 
the increased number of parameters, the corrected Akaike information criterion [128] and 
the Akaike weight [129] are applied to evaluate the consistency between the models and 
the experimental data. These criteria provide a measurement of the goodness of fits from 
the models by penalizing the models with more parameters and awarding the models with 
less sum of squares error. The corrected Akaike information criterion (AICc) is a 
modified version of the Akaike information criterion (AIC) for small sample sizes, and is 
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where Nd is the number of data points, Np is the number of parameters, and SSE is the 
sum of squares error. The Akaike weight reflects the probability that a model describes 
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  (2.2) 
where NM is the total number of models for comparison and  cAICi   is the difference 
between the AICc of model i and the minimum AICc from the model set. As shown in 
Table 2.1, the single-stage model’s SSE is larger than the SSE for the two-stage model; 
the Akaike weight of 97% compared to 3% indicates that two-stage model is the more 
likely description of the experimental data. Hence, the two-stage model is more 
consistent with the physical phase change and the chemical step change in member 
concentrations correlated in time. 
Table 2.1 – AICc analysis for the fits from the model in Figure 2.3 to the NF-CHO 
network concentrations with single- and two-stage models. Nd is the number of data 
points, and Np is the number of parameters. 
Model Nd SSE Np AICc Akaike weight (%) 
Single-stage 60 1.41 8 -207 2.94 
Two-stage 60 0.81 16 -214 97.1 
 
 The evolution of the NF-CHO network does not stop in the particle phase. 
Although the chemical exchange remains in equilibrium between 21-48 hr (Figure 2.6), 
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the particles continue to grow in size by either particle fusion or Ostwald ripening [130, 
131]. For the later, large particles grow by consuming the smaller ones given the driving 
force to lower the total surface area and to minimize the energy in the system. Also, the 
TEM images show that the particle phase is metastable and transitions into a fiber-rich 
phase (Figure 2.5c, d). The emergence of the fibers ends the particle stage and shifts the 
equilibrium between the species again. In this third stage, the fiber stage, the 
concentration of trimer increases significantly (Figure 2.7), which implies that the linear 
trimers are the component of the fibers. To identify the composition of the fibers, the 
fibers are spun down at 16,000 × g for 30 minutes, and then re-suspended in 40% ACN 
after the supernatant is removed. As the particles are not spun down, HPLC identifies the 
re-suspended portion as linear trimer assemblies (Figure 2.8), whose peak has the same 
retention time as in Figure 2.2. 
 
Figure 2.7 – Kinetics of the NF-CHO DCN in two weeks. Image adapted from Ref. 




Figure 2.8 – HPLC analysis of the fibers in NF-CHO network. Image adapted from 
Ref. [126] with permission. 
2.2.2 Kinetics of the NFF-CHO Network 
Similar to the NF-CHO monomer, the NFF-CHO monomer are synthesized with standard 
Boc-peptide synthesis followed by reduction with LiAlH4, which then gives the NFF-
CHO monomer. After the Boc protection group is removed with TFA, the activated NFF-
CHO monomer is incubated in 40% ACN aqueous solution to generate the network. The 
species in the network are separated with HPLC under quasi-neutral pH and identified 
with mass spectrometry. The incubated NFF-CHO network is composed of three main 
species: monomer, linear dimer and linear trimer, as shown in Figure 2.9.  
 
Figure 2.9 – HPLC analysis of the NFF-CHO network after two days of incubation. 
Image adapted from Ref. [126] with permission. 
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 The evolution of the NFF-CHO network is followed by HPLC and TEM with 
time, and a model is constructed based on the observed chemical and physical properties. 
The emergence of the particle and assembly phases in the NFF-CHO network is observed 
by TEM (Figure 2.10), and the assemblies are characterized as the trimer assemblies 
(Figure 2.11). The species distribution is followed by HPLC up to 336 hr, the end of the 
fiber stage. A kinetic model is developed to clarify the reaction mechanism in all three 
stages (Figure 2.12). The formation of linear dimer and linear trimer is formulated with 
bond formation (forward) rate constant (k1 and k3), while the backward constants are 
calculated based on the forward constants and the equilibrium constant (K2 and K4). For 
the linear trimer assemblies, a minimal autocatalytic assembly mechanism [66] is applied 
to the linear trimers. The assembly mechanism contains two steps: the assembly 
nucleation (k5) and the autocatalytic growth (k6). Combined together, the reaction 
mechanism for the NFF-CHO network is summarized in Figure 2.12.  
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Figure 2.10 – TEM images of the NFF-CHO network. Image adapted from Ref. 
[132] with permission. Scale bar = 200 nm. 
 
 
Figure 2.11 – HPLC analysis of the fibers in NFF-CHO network [126]. The 
assemblies are spun down under 16,000 × g and re-suspended after the supernatant 
is removed. The retention time of the re-suspended assemblies is the same as the 




Figure 2.12 – Kinetic steps for the NFF-CHO network. M, D and T represent 
monomer, linear dimer and linear trimer, respectively. k1 and k3 are forward rate 
constants while K2 and K4 are the corresponding equilibrium constants. TA is an 
assembled trimer in the fiber phase. T + TA represents the autocatalysis of 
unassembled trimer into fibers by pre-formed fibers. k5 and k6 are the rate constants 
for fiber nucleation and assembly.  
 The reaction mechanism fits the kinetics of the NFF-CHO network, which shows 
stage-wise evolution (Figure 2.13). In the first solution stage, the monomer concentration 
drops quickly within the first eight hours while the concentration of the linear dimer and 
linear trimer increases significantly (Figure 2.14). The fast condensation between the 
building blocks drives the oligomerization quickly, and the accumulation of longer 
oligomers triggers the formation of the particles, which causes distinct concentration 
changes. The phase boundary for model fits is assigned as halfway between the data 
points where distinct changes in concentrations are observed, and by this analysis the 
particle stage boundary is at 9 hr. This transition is significantly earlier than in the NF-
CHO network (21.5 hr as shown in Figure 2.6). The relatively fast formation of particles 
is consistent with the increased hydrophobicity from the additional phenylalanine of the 
NFF-CHO building block compared to NF-CHO.  
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Figure 2.13 – Fits of the model in Figure 2.12 for the NFF-CHO network. Three 
distinct stages of the network are observed over the 350 hrs. 
 
 
Figure 2.14 – Fits of the model in Figure 2.12 for the NFF-CHO network in the 
solution stage. 
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 The particle stage is the second stage of the NFF-CHO network evolution. In the 
particle stage, the linear trimer accumulates significantly, after which the network 
member distribution remains remarkably constant for a day (Figure 2.15). Although the 
ratios of the species concentration do not change, the size of the particles in the network 
increases between 19 – 48 hr (Figure 2.10). Similar to the NF-CHO network, the particles 
may grow via Ostwald ripening or particle fusion, and later the fibers emerge from the 
particles (Figure 2.10, 48 and 96 hr).  
 
Figure 2.15 – Fits of the model in Figure 2.12 for the NFF-CHO network in the 
particle stage. 
 At the end of the particle stage, the nucleation of the ordered trimer assembly is 
triggered inside the particles. Similar to Ostwald’s rule of stages [71] and the two-step 
nucleation [97], the trimers are organized into the ordered fiber structure from a 
metastable particle phase [72]. The trimer assemblies inside the particles are exposed to 
the solution phase after they grow long enough by consuming the other molecules in the 
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particles. The exposed trimer assemblies then take over the network by consuming the 
other trimers in the solution, and create a significant drop of both monomer and linear 
dimer (Figure 2.13). As more molecules are incorporated into the assembly phase, the 
concentration of the free molecules in the solution phase decreases, which makes the 
particle phase dissolve and disappear, as observed in Figure 2.10 at 96 hr.  
 AICc analysis is used to evaluate the validity of the boundaries in the mechanism 
to address over-fitting in NFF-CHO network modeling. The sigmoidal growth of the 
trimer concentration from solution to particle stages could be the result of self-templating 
(Figure 2.13). Thus, five models are evaluated here (Table 2.2): 1) a single-stage model 
(k1, K2, k3, K4), 2) a single-stage model with the autocatalysis (k1, K2, k3, K4, k5, k6), 3) a 
two-stage model (k1, K2, k3, K4 for both solution and particle stages), 4) a two-stage 
model with autocatalysis in both stages (k1, K2, k3, K4, k5, k6 for both stages), and 5) a 
two-stage model with autocatalysis in the particle stage (k1, K2, k3, K4 for Solution and k1, 
K2, k3, K4, k5, and k6 for particle stage). Only data for the first 50 hours are included to 
evaluate this boundary. AICc analysis (Table 2.2) supports the two-stage model, as the 
Akaike weights of the remaining models are close to zero; the two-stage model without 
catalysis is almost 99%, corroborating the boundary between the solution and particle 
stages. The emergence of the particle phase alters the equilibrium between the species, 
and the kinetic data cannot be described with the same parameter set. Also, AICc analysis 
shows that trimer accumulation is not autocatalytic in both stages; this suggests that the 
trimer do not self-template in the solution phase, and the particles do not serve as 
templates to drive the replication of trimer. 
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Table 2.2 – AICc analysis for the model in Figure 2.12 to the kinetic data of the first 
50 hours (solution and particle stages) of the NFF-CHO DCN. Single-stage includes 
k1, K2, k3 and K4 without a boundary. Single-stage with autocatalysis includes k1, K2, 
k3, K4, k5 and k6 without a boundary. Two-stage includes k1, K2, k3 and K4 for each of 
the solution and particle stages. Two-stage with autocatalysis in both stages includes 
k1, K2, k3, K4, k5 and k6 for each of the Solution and Particle Stages. Finally, two-
stage with autocatalysis in the particle stage includes k1, K2, k3 and K4 for the 
solution stage and k1, K2, k3, K4, k5 and k6 for the particle stage. Nd is the number of 
data points and Np is the number of parameters. 
Model Nd SSE Np AICc 
Akaike weight 
(%) 
Single-stage with no autocatalysis 30 2.33 4 -67.1 1.43 × 10-12 
Single-stage with autocatalysis 30 2.33 6 -61.0 6.91 × 10-14 
Two-stage with no autocatalysis 30 0.18 8 -131 98.7 
Two-stage with autocatalysis in both stages 30 0.18 12 -112 7.50× 10-3 
Two-stage with autocatalysis in particle stage 30 0.18 10 -122 1.26 
 The boundary between the particle and fiber stages in the NFF-CHO network is 
also validated by AICc, together with the autocatalytic nature of the assemblies. The 
models compared here are: 1) a single-stage model (k1, K2, k3, K4), 2) a single-stage 
model with autocatalysis (k1, K2, k3, K4, k5, k6), 3) a two-stage model with autocatalysis in 
fiber stage (k1, K2, k3, K4 for the particle stage and k1, K2, k3, K4, k5, and k6 for the fiber 
stage), 4) a two-stage with nucleation only in fiber stage (k1, K2, k3, K4 for the particle 
stage and k1, K2, k3, K4, and k5 for the fiber stage), and 5) two-stage with no assembly (k1, 
K2, k3, K4 for both the particle and the fiber stage) to fits of data from 9 to 336 hours 
(Table 2.3). Again both single-stage models (with and without k5 and k6) have Akaike 
weights close to zero, which confirms the different chemistry nature in the particle and 
the fiber stages. However, the AICc analysis does not support the autocatalytic nature (k6) 
for the fiber stage, which is common in amyloid self-assembly. The nucleation-only 
model (in Table 2.3) earns 88.3% of Akaike weight, which is higher than the 
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autocatalytic one (11.6 %). This shows that the resolution of our HPLC data is not 
sufficient to describe the autocatalytic nature of the NFF-CHO trimer assembly. To 
verify the autocatalytic nature of trimer assembly, fibers of the linear trimers from the 
NFF-CHO network are isolated by centrifugation, and sonicated in an ultrasonic bath to 
create more active ends. The sonicated seeds then are added into a new network with a 
1:10 ratio. As shown in Figure 2.16, the linear trimers of the seeded network accumulate 
more quickly compared to the unseeded network. This confirms the autocatalytic nature 
of growth of the trimer assemblies. 
Table 2.3 – AICc analysis for the model in Figure 2.12 to the kinetic data of 9 to 336 
hours (particle and fiber stages) of the NFF-CHO DCN. Single-stage includes k1, K2, 
k3 and K4 reactions without a boundary. Single-stage with autocatalysis includes k1, 
K2, k3, K4, k5 and k6 without a boundary. Two-stage with autocatalysis in the fiber 
stage includes k1, K2, k3 and K4 for the particle stage and k1, K2, k3, K4, k5 and k6 for 
the fiber stage. Two-stage with nucleation only in fiber stage includes k1, K2, k3 and 
K4 for the particle stage and k1, K2, k3, K4 and k5 for the fiber stage. Two-stage with 
no assembly includes for both the particle and the fiber stage. 
Model Nd SSE Np AICc Akaike weight (%) 
Single-stage with no autocatalysis 30 8.48 4 -28.3 4.60 × 10-15 
Single-stage with autocatalysis 30 6.21 6 -31.6 2.38 × 10-14 
Two-stage with autocatalysis in fiber stage 30 0.52 10 -90.0 11.6 
Two-stage with nucleation only in fiber stage 30 0.53 9 -94.0 88.3 




Figure 2.16 – Autocatalytic nature of the trimer assembly in NFF-CHO by seeding 
the network. (a) Growth of linear trimer and other network members in NFF-CHO 
Network without seeding. (b) Growth of linear trimer and other network members 
in NFF-CHO Network with the seeds (1:10) of trimer assemblies. Image adapted 
from Ref. [132] with permission. 
 
2.2.3 Compare the NF- and NFF-CHO networks 
The evolution pathway of NF- and NFF-CHO networks is similar, as they both undergo 
two same phase transitions. The emergence of the particle phase is triggered by the 
accumulation of the longer oligomers, which reach their solubility and precipitate. The 
formation of the particle phase is similar to the liquid-liquid phase separation in protein 
or peptide aggregation [133, 134]. The condensed metastable particle phase helps to 
overcome the initial desolvation, and provides an environment for the more 
thermodynamically favored fiber phase to nucleation. This “two-step nucleation” process 
has been observed in other systems, such as crystallization of proteins [70, 78-83] and 
minerals [87, 88]. However, the major difference between the DCN phase transitions and 
the other two-step nucleation system is the interplay between the physical and chemical 
properties of the networks. 
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 The network evolution is complicated as the physical and chemical distributions 
are affecting each other. As shown in Figure 2.17, after the monomers oligomerize into 
longer species, the first physical phase transition (particles) is triggered due to the 
accumulation of the insolvable oligomers. As suggested by the modeling results, the new 
physical phase changes the chemical nature of the network, and drives the redistribution 
between the species. Finally, as the second phase transition, the emergent fiber phase 
contributes to the second chemical redistribution between the species. Both NF- and 
NFF-CHO networks evolve in this process, and in both networks the linear trimers are 
selected to assemble, perform self-template, and predominate in the network with low 
dispersity and high fidelity.  
 
Figure 2.17 – The evolution of the chemical and physical dimentions in DCNs. 
 The apparent difference of NFF- from the NF-CHO network is the absence of the 
cyclic molecules. In the NF-CHO network, cyclic dimers and trimers are observed since 
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the solution stage, but the reversible cyclization is hindered in the particle stage, based on 
the constant cyclic dimer concentration in Figure 2.6. As the particles may disfavor the 
reversible cyclization of the oligomers, the early appearance of the particles in the NFF-
CHO network may limit the cyclic products. Due to the extra phenylalanine, the NFF-
CHO oligomers are more hydrophobic and nucleate particles more quickly. The time 
window for NFF-CHO oligomers to cyclize is shorter, and thus the cyclic molecules are 
not detected via HPLC. 
 Both NF-CHO and NFF-CHO networks follow complex kinetic mechanisms, and 
they require distinct kinetic constants associated with different stages timed to physical 
phase transitions. Additional constraints on particle number, size distribution, growth 
kinetics, and internal structure will be important to a more detailed mechanistic model to 
cover both the physical and chemical transitions. However, at this point the chemical and 
physical distributions combine to create dynamics consistent with elementary mass action 
kinetics. 
2.3 Conclusion 
In this chapter, the construction and analyses of two dynamic combinatorial networks 
(DCNs) are discussed, which are built from the NF- and NFF-CHO monomers 
individually. Without enzymes driving the oligomerization, these networks show ability 
to synthesize sequence-defined oligomers with low dispersity via self-templating. 
 With the experimental results and model discrimination combined, it is shown 
that the evolution of both networks is stage-wise, and the chemical and physical 
properties of the networks are essential to derive the final state. As the complex 
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interaction between the physical and the chemical dimensions complicates the design of 
new networks, the entire process may be simpler to design and engineer if the two-step 
nucleation process is better understood.  
2.4 Methods 
2.4.1 Materials 
All commercially available chemicals are obtained from Sigma-Aldrich, AnaSpec, Nova 
Biochem, and Acros organics. HPLC grade acetonitrile and water are obtained from 
Sigma-Aldrich and/or Fisher Scientific, and distilled deionized water for sample 
preparation is obtained from EMD chemicals Inc.  
2.4.2 Synthesis of NF-CHO 
 
Figure 2.18 – Reaction pathway to synthesize the NF-CHO monomer. 
The NF-CHO monomers are synthesized following Figure 2.18. In step a, N-Boc-L-Phe 
(molecule 1) is dissolved in dichloromethane and reacted with 1,1-carbonyldiimidazole 
and N,O-dimethylhydroyxlamine hydrochloride to obtain Boc-Phe-weinreb (molecule 2). 
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The t-butoxycarbonyl protecting group (Boc group) is then removed by HCl (step b) to 
result molecule 3, which is then coupled with Boc-Asn (step c) to gain molecule 4. After 
the Boc-Asn-Phe-weinreb molecule 4 is reduced (step d), the Boc group of the reduced 
product 5 from step d is removed to access the free monomer 6, NF-CHO monomer. The 
detailed steps for synthesizing the NF-CHO molecule are indicated in Ref. [132]. 
2.4.3 Synthesis of NFF-CHO 
 
Figure 2.19 – Reaction pathway to synthesize the NFF-CHO monomer. 
The NFF-CHO monomer is synthesized by following Figure 2.19. To synthesize the 
NFF-CHO monomer, N-Boc-L-Phe (molecule 1) is reacted with 1,1-carbonyldiimidazole 
and N,O-dimethylhydroyxlamine hydrochloride to obtain Boc-Phe-weinreb (molecule 2). 
The t-butoxycarbonyl protecting group (Boc group) is then removed by HCl (step b), and 
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the resulting product 3 is coupled with Boc-Asn (step c) to gain molecule 4. In step d, the 
Boc group on Asn is removed with HCl, and the resulting molecule 5 is coupled with 
Boc-Asn (step e) for molecule 6, Boc-Asn-Phe-Phe-weinreb amide. After the reduction 
of the C-terminus of molecule 6, the Boc group at the N-terminus of molecule 7 is 
removed to deprotect and activate the free monomer NFF-CHO, molecule 8. The detailed 
synthesis procedure for NFF-CHO is in Ref. [132]. 
2.4.4  Preparation of the Dynamic Combinatorial Network Solution 
After final deprotection by trifluoroacetic acid (TFA) of the network monomer, Boc-NF-
CHO or Boc-NFF-CHO, TFA is removed and the monomer is dried under vacuum under 
room temperature. To start the network incubation, the dried monomer is then dissolved 
in 40% acetonitrile in water with N2 protection; dissolution of the monomer is assisted by 
vortexing and bath sonication until solution becomes clear.  
2.4.5 HPLC and LC-MS Analyses of the DCNs 
The species of the DCNs are separated and quantified with HPLC. Separation of the 
DCN members is performed with Waters Delta 600 with reversed-phase column 
(Kromasil 100-5C18, 4.6 × 250mm) with the mobile phase flow rate equal to 1.0 
mL/min. The mobile phase is from 10% to 90% acetonitrile, with the gradient of 2% 
acetonitrile/min. UV absorbance is monitored at both 258nm (for Phenyl ring side chain 
absorption) and 222nm (for amide bond absorption). LC-MS analyses are performed on 
Waters Synapt G2 MS/Acquity UPLC system to separate and characterize the species.  
2.4.6 Transmission Electron Microscopy 
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The morphologies of the macrostructures of the DCNs are observed with transmission 
electron microscopy (TEM). The DCN solution is loaded onto the copper grid for 3 min, 
and the excess solution is wicked away with filter paper. The resulting grid is negatively 
stained with 5% uranyl acetate in water for three minutes before the stain solution is 
removed with filter paper. The grid is then stored in a vacuum desiccator overnight to 
remove the remaining liquid. TEM images are recorded with a Hitachi H-7500 
transmission electron microscope.  
2.4.7 Model Construction and Discrimination 
The kinetic models are constructed to describe the evolution of the DCN distribution. The 
oligomerization reactions are assumed to be reversible; the bond forming reactions are 
expressed in its reaction constant and the reverse reactions are expressed with the 
combination of both the bond forming reaction and the equilibrium constants. Assembly 
kinetics are modeled with the two-step process proposed by Finke [66], which includes 
an assembly nucleation step and an autocatalytic assembly growth step. The models are 
fit to the member concentrations by minimizing the sum of square error (SSE) between 
the calculated and experimental values [135]. A Latin Hypercube sampling [136] 
provides the initial guesses for the parameters and the optimization procedure is carried 
out with the fmincon function in MATLAB 2012a (The Mathworks, Inc). Model 
discrimination is achieved with the corrected Akaike information criterion (AICc) [129] 
to verify the consistency of the models and the experimental data.  
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CHAPTER 3.  
A KINETIC MODEL FOR TWO-STEP NUCLEATION 
OF PEPTIDE ASSEMBLY 
3.1 Introduction 
In Chapter 2, it is demonstrated that the chemical distribution in the DCNs is affected by 
the emergent physical phases. After a solution stage, both the NF-CHO and the NFF-
CHO trimer assemblies dominate the system via a metastable particle phase. In this 
chapter, this complex process is mathematically modeled. First, the peptide assembly for 
a monodisperse system is modeled with a two-step nucleation pathway, and the 
monodisperse model shows the capability to rationally explain the kinetics of A(16-22) 
assembly in various acetonitrile-water solvent mixtures. Finally, this monodisperse model 
is expanded to a polydisperse model with peptide oligomerization, and both the final 
chemical distribution and the physical distribution are discussed. 
3.2  Results and Discussion  
3.2.1 Development of a peptide assembly model with two-step nucleation 
For a monodisperse system, the peptide self-assembly under two-step nucleation starts 
with the formation of the metastable particle phase (Figure 3.1a and Figure 3.1b). This 
particle nucleation is assumed to be analogous to nucleation of droplets in vapor or 
solution, which follows the classical nucleation theory [72, 137, 138]. The particle 
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in which p1 and p2 are peptide concentration-independent constants. S is the 
supersaturation for particles, defined as the ratio of peptide concentration (C) over the 
solubility of particles (C1*) such that 1*/S C C . The solubility of particles is estimated 














where mon is the peptide density, Wmon is the peptide molecular weight and  is the Flory-
Huggins parameter. The typical density of protein and molecular weight of peptide Ac-
KLVFFAE-NH2 are used for mon and Wmon, respectively (Table 3.1). The miscibility of 
the peptide and the solvent is critically tied to the Flory-Huggins parameter (). As  
increases, the peptide solubility for particles decreases, and the peptides then have a 
stronger propensity to nucleate particles. Figure 3.2a shows the simulated A(16-22) 
peptide solubility as a function of the Flory-Huggins constant (), and Figure 3.2(b)-(d) 
show the development of the particle phase given different . The particle nucleus size 
and the particle growth mechanism are also required to calculate the phase distributions, 





Figure 3.1  The peptide assembly mechanism under two-step nucleation. (a) 
Initially, peptides are dissolved in the solution, and (b) the metastable peptide 
particles nucleate if the peptides are not completely soluble. (c) The particles grow 
when the solution is supersaturated for particles. (d) Later, the assemblies nucleate 
inside the particles, and (e) extend into the solution after growing into a critical size 
by consuming the peptides inside the particles. (f) The assemblies propagate by 
consuming the free peptides in the solution phase, which decreases the free peptide 
concentration. (g) The particles start to dissolve when the solution becomes 
undersaturated for particles. (h) If assembly dissolution is negligible, after all free 





Table 3.1  Summary of values for the mathematical model in equations (3.1) to 
(3.10). 
Parameter Description Units Value 
p1 Prefactor for particle nucleation rate L-1 sec-1 1014 
p2 Constant in the exponential part of 
the particle nucleation rate (R1) 
– 100 
mon Density of peptide g cm-3 1.4 
 Flory-Huggins parameter – 7.5–12 
Wmon Molecular weight of peptides g mole-1 894 
 Interfacial tension between peptide 
and solvent 
g s-2 15 
kb Boltzmann constant J K-1 231.38 10  
T Temperature K 300 
NA Avogadro’s number mole-1 236.023 10  
kg0 Kinetic constant for particle growth mole-1 sec-1 100–104 
kn Assembly nucleation constant sec-1 10-7 
kAG Assembly growth constant inside the 
particle, (R4) 
sec-1 10-2 
par Particle density g cm-3 1.4 
kg Assembly growth constant in the 
solution phase, (R6) 
mole-1 sec-1 102 
kbp Prefactor of Assembly dissolution sec-1 1010 
G Binding energy between peptides in 
the assembly 
J 10-19.1–10-18.8 
C0 Initial peptide concentration mM 0.5–1 





Figure 3.2  The peptide solubility for particles as a function of the Flory-Huggins 
constant (). (a) The peptide becomes less soluble as  increases. (b) Simulation of 
the particle phase development with  = 6. (c) Simulation of the particle phase 
development with  = 8. (d) Simulation of the particle phase development with  = 
10. The parameters used for these simulation are taken from Table 3.1 with kn = 0, 
kg0 = 10 mole-1 sec-1 and C0 = 1 mM. 
 A stable particle nucleates with a critical number of peptides to overcome the 
interfacial energy with the bulk free energy change. This critical number (n*) is then the 



















where  is the interfacial tension between peptide and solvent, kb is Boltzmann’s constant, 
NA is Avogadro’s number, and T is the temperature, which is set as a constant in this 
study. Whenever a particle is formed, n* peptides are removed from the solution phase 
and form a new particle. Equation (3.3) suggests that, under a supersaturation S, a particle 
remains stable against dissolution as long as its size is at least n*; hence, the stability of a 
particle depends on its size, and so does the peptide solubility of that particle [130, 142, 
143]. However, here the peptide solubility of all particles is assumed to be size-
independent [144-146] for simplicity.  
 The particles may grow or dissolve (Figure 3.1c), which depends on the solubility 
of particles (C1*). When particle growth is bulk diffusion-limited, the net particle growth 
rate for an individual particle with x peptides may be expressed as [143, 145]: 
    1/32 0 1*gr x k x C C   (3.4a) 
and the overall particle growth rate for all the particles with x peptides is: 
      1/32 0 1*gR x k x C C P x   (3.4b) 
where kg0 is the particle growth constant and P(x) is the total number of particle with x 
peptides. This net expression results in either particle growth or dissolution based on the 
peptide concentration in the solution phase, C. When C > C1*, solution is supersaturated 
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for particle and particles grow according to R2 until C = C1*. On the other hand, when C < 
C1*, the solution is undersaturated and the particles dissolve until C = C1*. Thus for all 
particles, both their growth and dissolution stop when C = C1* and they never happen 
simultaneously. 
 Assemblies nucleate inside the metastable particles (Figure 3.1d). As the 
assembly nucleation rate (R3) is a function of particle mass [97, 147], R3 for the particles 
with x peptides is formulated as: 
    3 nR x k P x x  (3.5) 
where kn is the assembly nucleation constant. The assembly nucleus size is assumed to be 
two, the minimal number to form assemblies with an intermolecular bonding [65]. As the 
peptide concentration in the particles is fixed, it is not explicitly represented in equation 
(3.5). Once the reaction happens, two of the peptides in the particle become an assembly, 
and the assembly grows by consuming the other peptides in the same particle. The net 
assembly growth rate inside particles with x free peptides (R4) is expressed as [90]:  
    4 AG pR x k A x  (3.6) 
where kAG is the growth constant and Ap(x) is the total number of assemblies in particles 
with x peptides. With R3 and R4, multiple nuclei may nucleate and grow within the same 
particle, as observed previously [148]. This makes the model more flexible compared to 
other studies [72, 97, 147], which are limited to one nucleus per particle at most.  
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 Once the assemblies grow long enough, their sizes (LA) become greater than the 
particle diameter (LP), and thus they are exposed to the solution phase (Figure 3.1e). By 
assuming that the assembly propagates at the two ends, LA for an assembly containing y 
peptides is then calculated as  0.5 1y   nm, where 0.5 nm is the typical spacing between 
peptides in the assemblies [149]. The particle diameter is calculated by assuming that the 
particle density (par) is similar to the typical protein density (Table 3.1). The diameter 
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 Before the sizes of the assemblies reach the critical value LP, the assemblies stay 
in the particles. Once an assembly with y peptides emerges into the solution, those y 
peptides are then removed from the particle phase and added into the assembly phase 
(Figure 3.1f, Figure 3.1g, and Figure 3.1h). The following growth of assembly in the 
solution phase is formulated as a function of the remaining peptides in the solution phase, 
and the corresponding growth rate (R5) for assemblies with y peptides is:  
    5 2 gR y k A y C  (3.8) 
where kg is the assembly growth constant in solution phase, and A(y) is the concentration 
of assemblies with y peptides in the solution phase. The leading “2” in R5 stands for the 
two active ends per assembly. The peptide dissociation may occur at the assembly ends 
due to instability. The assembly dissolution rate (R6) is formulated as: 
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where kbp is the prefactor of the rate constant, G is the binding energy[150] between the 
assembled peptides, and B(y) is the number of breakable bonds at the assembly ends. If y 
= 2, there is only one bond breakable and thus B(y) = 1; if y > 2, both the bonds at the 
ends are breakable and B(y) = 2. The dissolution rate constant is expressed in an 
Arrhenius-type instead of a single constant to keep it flexible enough to predict an 
assembly system with peptide oligomerization [98], whose binding energy is proportional 
to the oligomer length [150]. When the assembly formation inside the particle is not 
significant, the concentration of the assembled peptides changes only when the assembly 
grow or dissolve. Thus, the assembly phase reaches a steady state if the assembly growth 
rate (R5) and the assembly dissolution rate (R6) are equal; given R5 = R6, the solubility of 
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 Figure 3.3 shows the solubility for assembly as a function of the stacking energy 
between the assembled peptides (∆G). As ∆G increases, the peptide solubility for 
assemblies decreases significantly (Figure 3.3a); the assemblies become stable and start 
to accumulate by consuming the other phases (Figure 3.3(b-d)). 
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Figure 3.3  The peptide solubility for assembly as a function of the assembly 
stacking energy (ΔG). (a) The peptide becomes less soluble as (ΔG) increases. (b) 
Simulation of the assembly phase development with ΔG = 10-20 J. (c) Simulation of 
the assembly phase development with ΔG = 1.14 × 10-19 J. (d) Simulation of the 
assembly phase development with ΔG = 10-17 J. The parameters used for these 
simulation are taken from Table 3.1 with  = 8, kg0 = 10 mole-1 sec-1, and C0 = 1 mM. 
 
3.2.2 Simulation of the Peptide Assembly Model with Two-step Nucleation  
 The developed model is executed with the Monte Carlo algorithm, and three 
parameters are selected to simulate the transition from the particle phase to the assembly 
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phase. The particle growth constants (kg0) and Flory-Huggins parameters () are varied to 
investigate the transition of the metastable particle phase, while the stability of 
assemblies and the assembly dissolution rate are varied as a function of stacking energy 
of the peptides (G). To verify the threshold supersaturation for particle nucleation, the 
lower limit of  is selected to make the peptide solubility close to the initial peptide 
concentration of 1 mM, while the upper limit is selected to make the peptide extremely 
insoluble (Figure 3.2a). The upper and lower limits for G are selected to span the range 
from very soluble to extremely insoluble, under a 1 mM peptide concentration (Figure 
3.3a). By changing kg0, the contribution of the net particle growth rate may be 
investigated without altering the thermodynamic properties of the system. 200 parameter 
sets are generated based on these three variables with a Latin hypercube sampling [136], 
with parameter ranges given in Table 3.1. The results presented here are simulated up to 
100 hr as a practical experimental time scale, and the behaviors of the model under these 
parameters are classified in Table 3.2. For the details about the criteria categorizing these 
results, see Section 3.4.2 in Methods. 
Table 3.2  Distribution of simulation results from the general model with 200 
parameter sets.  
Case Number of cases Percentage (%) 
1. Pure solution phase 7 3.5 
2. Pure assembly phase 52 26 
3. Solution-assembly equilibrium 16 8 
4. Solution-particle equilibrium 103 51.5 
5. Three-phase equilibrium 5 2.5 
6. Slow kinetics  17 8.5 
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 For some parameter sets, the simulated results show no particle formation within 
the reaction time (Figure 3.1). There are seven parameter sets (3.5%) that remain in this 
pure solution phase (Case 1). For all parameter sets, at the initial time the solution is 
supersaturated since the free peptide concentration C is greater than the solubility of 
particles C1*. Thus, the supersaturation for particles, defined as S = C/C1*, is greater than 
one. However, the peptides will not form particles within the reaction time unless the 
solubility C1* is below a threshold value [90], and this threshold value controls the 
particle nucleation kinetics. As shown in Figure 3.4, within the reaction time of 100 hr, 
the particles do not nucleate unless the initial supersaturation is greater than 1.35. The 
threshold value for particle nucleation is then around 0.74 mM, based on this critical 
supersaturation of 1.35 and the initial peptide concentration of 1 mM. A supersaturation 
between 1.0 and 1.35 is then defined as the metastable zone for particle formation. 
Particles nucleate within the reaction time only when the supersaturation for particles is 




Figure 3.4  Threshold supersaturation to trigger particle nucleation. The particles 
nucleate within the simulation time only when the initial supersaturation is greater 
than 1.35; the corresponding threshold value for particle nucleation is 0.74 mM. The 
maximum particle mass concentration for each parameter set is defined as the 
maximum peptide concentration in the particle phase within the reaction time.  
 Under two-step nucleation, the metastable particles transition as the assembly 
phase matures. As illustrated in Figure 3.5 for a single parameter set, all peptides are 
consumed by the assembly phase and this result is categorized as the pure assembly phase 
(Case 2 in Table 3.2). As shown in Figure 3.6, Case 2 on average has the highest G 
compared to the other cases. The assemblies in the solution phase do not consume the 
peptides inside the particle phase directly. Rather, once the solution is undersaturated for 
particles, the particles start to dissolve and release the peptides into the solution. The 




Figure 3.5  The assembly phase dominates after the solution and the particle phase 
vanish.  The particles nucleate since the peptide solution is saturated and vanish 
after the peptides are depleted because of the consumption from the assembly phase. 
The parameters used for this simulation are taken from Table 3.1 with kg0 = 16.6 




Figure 3.6  Average stacking energy (G) for Case 2 (pure assembly phase), Case 3 
(solution-assembly equilibrium), Case 4 (solution-particle equilibrium) and Case 5 
(three-phase equilibrium).  
 If the free peptides are soluble for assemblies due to a weaker stacking energy, 
G, the free peptides may coexist and equilibrate with the assemblies, as illustrated in 
Figure 3.1g and Figure 3.7. This solution-assembly equilibrium is classified as Case 3 in 
Table 3.2. The final peptide concentration, determined by the solubility of assemblies, is 
not sufficient to sustain the particles. The metastable particle phase dissolves as in Case 
2, and the difference between Case 2 and Case 3 is the reversibility of assembly growth. 
In Case 2 the growth of assemblies is nearly irreversible, while Case 3 is obtained when 
the assemblies exhibit significant reversibility.  
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Figure 3.7  The system reaches equilibrium between the solution and the assembly 
phases. The particle phase vanishes after the assembly phase becomes dominant, 
while assemblies are still partially soluble. The final state is the equilibrium between 
the solution and the assembly phases. The parameters used for this simulation are 
taken from Table 3.1 with kg0 = 128.3 mole-1 sec-1,  = 10.25, G = 1.23 × 10-19 J, and 
C0 = 1 mM. 
 When the stacking energy of assemblies is not strong enough, the assemblies 
cannot grow in the solution. The remaining solution and particle phases reach equilibrium 
with each other, as shown in Figure 3.1c, Figure 3.1d and Figure 3.8. This solution-
particle equilibrium occurs in over half of the parameter sets (Case 4 in Table 3.2), and is 
characterized by the absence of the assembly phase. As shown in Figure 3.1, on average 
Case 4 has the weakest stacking energy (G) compared to the other cases with an 
assembly phase, and this solution-particle equilibrium has been experimentally observed 
[21]. Kinetically limiting the assembly nucleation rate (kn) may also result in achieving a 
stationary state between the solution and particle phases [72]. Under this condition, the 
particle phase develops and coexists with the solution phase because the assembly 
nucleation rate is extremely slow, and the system remains kinetically trapped.  
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Figure 3.8  Equilibrium between particle and solution phases is achieved when the 
assemblies are not stable. The assemblies may not be stable enough to maintain a 
positive growth rate. The remaining phases are the particle and the solution phases. 
The parameters used for this simulation are taken from Table 3.1 with kg0 = 128.3 
mole-1 sec-1,  = 10.25, G = 1.23 × 10-19 J, and C0 = 1 mM. 
 When both the assembly and particle phases are observed and the distribution 
between phases reaches a stationary state, the relatively rare three-phase equilibrium can 
be observed (Figure 3.1f and Figure 3.9). Both particle and assembly supersaturations are 
crucial to achieving the coexistence of all three phases (Figure 3.10). When the particle 
phase has the higher solubility, it is eliminated and the result is classified as either Case 2 
or 3. When the assembly phase has the higher solubility, the result is classified as the 
solution-particle equilibrium (Case 4). To obtain the rare three-phase equilibrium (Case 
5), the solubilities for particles and assemblies need to be high enough to maintain the 
solution phase, and close enough to each other to stabilize both phases. Figure 3.10 
suggests that the final equilibrium states can be rationally predicted as a function of the 
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solubilities for particles and assemblies, as they are influenced by the Flory-Huggins 
parameter () and the stacking energy of the assemblies (G), respectively. 
 
Figure 3.9  The rare 3-phase equilibrium is achieved when both particle and 
assembly phases exist. The parameters used for this simulation are taken from 





Figure 3.10  Average final supersaturations for particles and assemblies determine 
the final phase distribution. The numbers in the parentheses are the numbers of 
results in each case. 
 The final states of a 1.0 mM peptide solution are simulated with different 
solubilities for particles and assemblies (Table 3.3). For a 1 mM peptide solution, both 
solubilities are in the range from 0.005 mM (least soluble) to 1.1 mM (totally soluble). 
Figure 3.11 shows the prediction of the solubility difference between the particle and 
assembly phases based on Table 3.3, with equation (3.2) and equation (3.10) used to 
derive the particle ( *1C ) and assembly (
*
2C ) solubilities, individually. The diagonal of 
Figure 3.11 represents the equal solubility between the two phases; the region above the 
diagonal represents the assembly-rich results while the region below the diagonal 
represents the particle-rich results. Although Figure 3.11 predicts the final 
thermodynamic states, it does not take the kinetic information into consideration. 
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Figure 3.11  The solubility difference between the particles and the assemblies as a 
function of the Flory-Huggins constant () and the stacking energy (ΔG). The ranges 
of the  and ΔG values in Table 3.3 and the parameter values in Table 3.1 are used. 
The difference is calculated as the solubility difference between particles and 
assemblies: 1* 2*C C . 
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Table 3.3  Flory-Huggins parameter () and stacking energy of assembly (G) used 
in Figure 3.12. The values in the parentheses indicate the corresponding solubility 
for particles and assemblies given the Flory-Huggins parameter () and stacking 
energy (G), respectively. 
 ( and solubility 
for particles, mM) 
G (J) (and solubility 
for assemblies, mM) 
12.65 (0.005) 
9.66 (0.1) 
1.297 × 10-19 (0.005) 
1.173 × 10-19 (0.1) 
8.97 (0.2) 1.144 × 10-19 (0.2) 
8.56 (0.3) 1.128 × 10-19 (0.3) 
8.27 (0.4) 1.116 × 10-19 (0.4) 
8.04 (0.5) 1.107 × 10-19 (0.5) 
7.86 (0.6) 1.099 × 10-19 (0.6) 
7.71 (0.7) 1.093 × 10-19 (0.7) 
7.57 (0.8) 1.087 × 10-19 (0.8) 
7.46 (0.9) 1.082 × 10-19 (0.9) 
7.35 (1.0) 1.078 × 10-19 (1.0) 
7.26 (1.1) 1.074 × 10-19 (1.1) 
 Figure 3.12 shows the kinetic simulation with the entire two-step nucleation 
model, from equation (3.1) to equation (3.9), as a function of the Flory-Huggins constant 
() and the stacking energy (ΔG). As shown in Figure 3.12, no particle forms when the 
solubility of particles is equal to or greater than 0.8 mM, consistent with the threshold 
value (0.74 mM) obtained from Figure 3.4; this pure solution phase is not predicted in 
Figure 3.11, which does not include the kinetic information. When the solubility of 
particles is equal to or less than 0.7 mM, different phase equilibria are observed. The 
assemblies survive when they are less soluble than the particles, and vice versa. The rare 
three-phase equilibrium is reproduced with equal solubilities for particles and assemblies, 
as predicted. However, when both the solubilities of particles and assemblies are as low 
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as 0.1 mM, the transition to the three-phase equilibrium becomes slow and does not reach 
a steady state within the reaction time. Such slow kinetics, which are classified as Case 6, 
will be further discussed below. 
 
Figure 3.12  Final states predicted by the model for 1.0 mM peptide solution as a 
function of solubilities for particles and assemblies. The parameter sets are listed in 
Table 3.1 and Table 3.3 with kg0 = 104 mole-1 sec-1, and C0 = 1 mM, except kn = 0.5 × 
10-7 sec-1. kn is decreased from 10-7 sec-1 in Table 3.1 to ensure that the solubility of 
the assemblies is not affected by the assembly nucleation in the particles, and thus 
three-phase equilibrium may be achieved within the reaction time.  
 Not all parameter sets achieve their final thermodynamic equilibria by the end of 
the reaction time. Although most of the parameter sets do predict a final distribution 
within the reaction time of 100 hr, 17 out of 200 parameter sets exhibit slow kinetics 
(Case 6), and the unfinished reactions are attributed to slow particle dissolution (Figure 
3.13). Although the assembly phase is already growing outside of the particles, the 
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relatively stable particle phase dissolves slowly even though the free peptide 
concentration is close to zero. On average, the parameter sets contributing to slow 
kinetics have the lowest particle growth constant (kg0), as shown in Figure 3.14. Particle 
dissolution, which shares the same rate equation with particle growth (equation (3.4a) and 
(3.4b)), delays the entire process and thus the process remains unfinished after 100 hr. To 
verify the importance of this kinetic constant without changing the final thermodynamic 
distribution, the simulation in Figure 3.13 is repeated with kg0 increased to its upper limit 
indicated in Table 3.1. With fast particle dissolution, the peptide self-assembly process is 
finished within the reaction time (Figure 3.15). Taken together, these results demonstrate 
that the final states in peptide assembly via 2SN are controlled principally by the Flory-
Huggins parameter and the peptide stacking energy. The system may be slowed by a 
small particle growth constant controlling both the particle growth and dissolution rates, 
such that assembly growth is delayed due to the scarce peptide resource in solution.  
 
Figure 3.13  The slow particle dissolution makes the kinetics slow. The parameters 
used for this simulation are taken from Table 3.1 with kg0 = 2.16 mole-1 sec-1,  = 
10.80, G = 1.51 × 10-19 J, and C0 = 1 mM. 
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Figure 3.14  Average particle growth constant (kg0) for Case 2 (pure assembly 
phase), Case 3 (solution-assembly equilibrium), Case 4 (solution-particle 
equilibrium), Case 5 (three-phase equilibrium) and Case 6 (slow kinetics). On 
average, Case 6 has the lowest particle growth rate constant. The numbers in the 
parentheses are the number of results in those cases. 
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Figure 3.15  The slow kinetics in Figure 3.13 reach the final state within the 
reaction time given the increased particle growth constant. The parameters used for 
this simulation are taken from Table 3.1 with kg0 = 104 mole-1 sec-1,  = 10.80, G = 
1.51 × 10-19 J, and C0 = 1 mM. 
3.2.3 The Model Predicts A(16-22) Assembly 
The structurally defined A(16-22) assemblies provide an opportunity to validate the 
model’s utility, and accordingly we incubated the purified A(16-22) peptide in different 
aqueous acetonitrile (ACN) mixtures to follow assembly maturation. We initially 
predicted the kinetics of A(16-22) assembly would be slower in more hydrophobic 
environments, where the assemblies are more soluble [21]. Here ACN is used to increase 
the solvent hydrophobicity and stabilize the free A(16-22) peptide. A series of 
topography images of A(16-22) solutions in 40% ACN are measured by transmission 
electron microscopy (TEM) over time. As shown in Figure 3.16a after one hour of 
incubation, 0.5 mM of A(16-22) is above the threshold value for particle nucleation in 
40% ACN. The particles are evenly distributed on the EM copper grid with homogeneous 
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particle sizes. In the TEM image of the sample incubated for five hours (Figure 3.16b), 
the fiber phase appears together with larger particles, while the density of particles 
decreases significantly. Such dynamic particle size variation shows the metastable phase 
to be distinct from amphiphilic micelles, whose sizes are determined by the monomer 
structure [151, 152]. Although Figure 3.16(a)-(c) show that the particle number decreases 
and particle size increases, these images on dried grids are not sufficient to accurately 
quantify the overall mass change of the particle phase. After 48 hours of incubation, the 
metastable particle phase is depleted and the stable fiber phase dominates the system 
(Figure 3.16c). This series of images indicates that A(16-22) assembles into fibers with 




Figure 3.16  TEM images of 0.5 mM A(16-22) solution in (a-c) 40%, (d-f) 60%, 
and (g-i) 80% acetonitrile in water. Images are taken after incubation for (a, d, and 
g) 1 hr, (b, e, and h) 5 hr, and (e, f, and i) 48 hr. Scale bar = 100 nm. 
 Incubation of A(16-22) in 60% and 80% ACN exhibits particle and assembly 
phases that are kinetically distinct from 40% ACN. Counter to our original hypothesis, 
the fiber maturation kinetics are now faster—fibers appear in 60% (Figure 3.16d) and 
80% (Figure 3.16g) conditions after 1 hour of incubation, in contrast to the pure particle 
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phase in 40% ACN (Figure 3.16a). The observed particle size at 1 hour also increases 
with increasing ACN concentration (Figure 3.16a, Figure 3.16d, and Figure 3.16g). 
Through these EM images, the properties of the dynamic particle phase, the particle size 
and the particle number, are certainly tunable with different solvent compositions. The 
final fiber assemblies remain unchanged in all three solvents (Figure 3.16c, Figure 3.16f, 
and Figure 3.16i) and mature through the same intermediate particle transitions (Figure 
3.16b, Figure 3.16e, and Figure 3.16h) [63]. These results are consistent with the 
morphological evolution of A(16-22) assemblies occurring under a 2SN process.  
 In addition to the TEM images, circular dichroism (CD) analyses provide time 
dependent evaluation of the assembly progress. While Thioflavin T (ThT) and Congo red 
(CR) are typically used to probe peptide assemblies and protein aggregation, they do not 
bind to A(16-22) assemblies in organic solvent [153, 154], and thus CD provides a 
valuable option. As shown in Figure 3.17a and Figure 3.18, the ellipticity at 217 nm [51] 
indicates that -sheets form immediately. By this analysis, A(16-22) assembles faster in 
80% ACN than in 40% ACN (Figure 3.17a), and all assemblies reach equilibrium by 48 
hr regardless of the solvent composition, consistent with the TEM analyses (Figure 3.16e, 
Figure 3.16f, and Figure 3.16i).  
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Figure 3.17  Kinetics of A(16-22) self-assembly (a) measured experimentally as a 
function of acetonitrile concentration and (b) simulated as a function the Flory-
Huggins parameter.(a) The CD intensity at 217 nm is normalized to the average 
value of the last three time points, when the signatures are stable and the kinetics 
reaches equilibrium. (b) As  decreases, A(16-22) assembles faster. Table 3.1 is 
used for the parameter set with kg0 = 200 mole-1 sec-1, kg = 5 mole-1 sec-1, G = 10-18.5 J, 
kn = 5 × 10-7 sec-1 and C0 = 0.5 mM.  
 
Figure 3.18  CD spectrum of 0.5 mM Aβ(16-22) in 40% ACN as a function of time. 
The negative signature at 217 nm develops as the β-sheet content increases, and is 
used as a probe to calculate the progress of assembly. 
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 FT-IR analyses of the final products verify amide stretches at 1625 and 1690 cm-1 
(Figure 3.19), consistent with anti-parallel -sheet amyloid fibers [155] under all 
conditions. Both TEM images (Figure 3.16) and IR spectra (Figure 3.19) then confirm 
that the structure of A(16-22) fibers are not ACN concentration-dependent, allowing the 
A(16-22) assembly kinetics under different ACN concentrations to be compared.  
 
Figure 3.19  FTIR spectra of A(16-22) assemblies in 40%, 60% and 80%.  The 
overlapping peaks suggest that the normal mode of peptide stacking is not ACN 
concentration-dependent. All spectra show a peak at 1625 cm-1 and another at 1690 
cm-1, which are the typical signatures for the anti-parallel β-sheet structure. 
 The experimentally observed kinetics contradict our original hypothesis that the 
assembly rate should be slower in more hydrophobic surroundings due to a reduced 
driving force. While the number of particles decreases and the particle size increases with 
increasing ACN concentrations (Figure 3.16a, Figure 3.16d, Figure 3.16g, and Figure 
3.20), the rate of assembly increases (Figure 3.17a) but the final equilibrium position is 
not impacted (Figure 3.21). These results are consistent with two key model parameters 
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describing the effect of varying ACN concentration. The model shows that the particle 
nucleation and particle growth rates are related to supersaturation C1* and thus the Flory-
Huggins parameter (), while the assembly growth rate depends directly on the rate 
constant (kg). The assembly growth constant kg is selected instead of the stacking energy 
(G) because the constant final equilibria suggest that stacking energy remains 
sufficiently large with different ACN concentrations (Figure 3.21). Accordingly, 
simulations with varied Flory-Huggins parameters () and assembly growth constants 
(kg) are specifically compared with the experimental data. 
 
Figure 3.20  The average particle diameter and concentration of A(16-22) after 
one-hour of incubation. (a) The average particle diameters and (b) average particle 
numbers after the Aβ(16-22) solution is incubated for one hour as a function of 
acetonitrile concentration.Both the particle diameters and numbers are obtained 




Figure 3.21  Ellipticity at 217 nm of A(16-22) self-assembly in 40%, 60% and 
80% as a function of time. The end time intensity for different solvents is similar, 
which suggests that the final equilibrium does not depend on the acetonitrile 
concentration. 
 The trends of the A(16-22) kinetics are simulated as a function of the Flory-
Huggins parameter (), and the peptides assemble more quickly as  decreases (Figure 
3.17b). As defined in the model and shown in Figure 3.22, when  increases, peptide 
solubility of particles (C1*) decreases, resulting in fewer free peptides in solution 
available for assembly. By comparing Figure 3.17a and Figure 3.17b,  and the ACN 
concentration appear correlated inversely, such that increasing the ACN concentration 
decreases  in the system. This observation is consistent with our original hypothesis, 
since higher solubility is predicted with a lower . However, the higher solubility of 
particles has the effect of speeding up rather than slowing down final assembly. 
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Figure 3.22  Simulation results of free A(16-22) concentration as a function of 
Flory-Huggins parameter (). As  increases, the peptide solubility of particle and 
thus the free peptide concentration decrease. Table 3.1 is used for the parameter set 
with kg0 = 200 mole-1 sec-1, kg = 5 mole-1 sec-1, G = 10-18.5 J, kn = 5 × 10-7 sec-1 and C0 
= 0.5 mM. 
 The observed inverse relationship between ACN concentration and Flory Huggins 
parameter (), as seen in the assembly fraction kinetics, can be further investigated by 
comparing particle size. The TEM images at one hour show that the particle size 
increases with increasing ACN concentration (see Figure 3.16a, Figure 3.16d, Figure 
3.16g, and Figure 3.20), while the observed particle density decreases. The corresponding 
model predictions show that particle size increases as  decreases (Figure 3.23a), with a 
corresponding decrease in particle density (Figure 3.23b). Thus, the inverse relationship 
between ACN concentration and Flory Huggins parameter  is further supported by the 




Figure 3.23  Simulation results of particle size distribution after one hour of 
reaction as a function of the Flory-Huggins parameter (). (a) Particle number 
concentration and (b) particle concentration are acquired with Table 3.1 as the 
parameter set with kg0 = 200 mole-1 sec-1, kg = 5 mole-1 sec-1, G = 10-18.5 J, kn = 5 × 10-7 
sec-1 and C0 = 0.5 mM.   
 The Flory-Huggins parameter is not the only parameter that may affect the 
assembly kinetics. The assembly growth constant (kg) increases the rate directly (Figure 
3.24), and the simulated results are consistent with the experimental kinetics (Figure 
3.17a). However, kg changes the assembly growth rate only and has no effect on early 
particle phase evolution, as shown in Figure 3.25. Neither the number of particles nor the 
average particle size changes with kg after one hour of incubation. Hence, although kg 
may increase with increasing ACN concentrations and accelerate assembly kinetics, it 
alone is not sufficient to explain the changes in the particle phase in different solvents, as 




Figure 3.24  Simulation results of 1 mM A(16-22) self-assembly as a function of 
the assembly growth constant (kg). As kg increases, KLVFFAE assemble faster. The 
parameters used for this simulation are taken from Table 3.1 with kg0 = 200 mole-1 
sec-1,  = 10, G = 10-18.5 J, and C0 = 0.5 mM. 
 
Figure 3.25  Simulation results of particle size distribution after one hour of 
reaction as a function of assembly growth constant (kg). (a) Particle number 
concentration and (b) particle concentration are acquired with Table 3.1 as the 
parameter set with kg0 = 200 mole-1 sec-1,  = 10, G = 10-18.5 J, and C0 = 0.5 mM. 
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 Originally ACN was expected to slow down the assembly kinetics of A(16-22) 
by increasing the hydrophobicity of the solvent, increasing the solubility of the free 
peptides, and decreasing the driving force for assembly. However, based on the 
experimental and calculated results together, ACN does appear to increase the solubility 
of particles, but does not significantly affect the more stable assemblies. As the solubility 
of particles increases with the hydrophobicity of the solvent, more peptides become 
available in the solution phase for assembly growth, which makes the overall kinetics 
faster. 
3.2.4 The Two-Step Nucleation Model for a Polydisperse System 
The model with two-step nucleation proposed in Section 3.2.1 is extended for 
polydisperse systems, in which the peptides may also undergo oligomerization, as 
discussed in Chapter 2. This extension makes the monodisperse model built in Section 
3.2.1 capable of simulating a polydisperse system, while the original monodisperse 
condition becomes a special case when the oligomerization does not happen.  
 For the oligomerization, the bond-forming rate constant and the equilibrium 
constant are assumed to be independent of the oligomer length, and the oligomerization 
mechanism is assumed to be the same as, for example, the polymerization of citric acid 
[156]: 
  (3.11) 
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where Li and Lm are the i- and m-th species. Two additional model parameters are added, 
where k1 is the forward (condensation) constant and K1 is the equilibrium constant. When 
K1 increases, the oligomers grow longer and the average oligomer length (j) increases as 
well (Figure 3.26). As the reaction is performed is a water-rich environment, the water 
concentration (W) is assumed to be constant.  
 
Figure 3.26  The oligomer distribution as a function of the oligomerization 
equilibrium constant (K1).   
 Similar to the monodisperse model in Section 3.2.1, supersaturation for particles 
(S) is required for calculating the nucleation, growth, and dissolution of the particles. 
Here, the entire species distribution is considered when determining the supersaturation 
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 The solubility (C1*) for the entire system is derived with Flory-Huggins theory as 
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where ρmon is the monomer density, Wmon is the monomer molecular weight, and χ is the 
Flory-Huggins parameter. Given the solubility (C1*) and the species concentration (C), 
the supersaturation of the solution (S) may be calculated as S = C / C1*. Similar to the 
particle nucleation in the dispersion polymerization system [157], here the particle 
nucleation is assumed to be following the classical nucleation theory [72, 137, 138], with 
rate equation expressed the same as equation (3.1). The particle nucleus size is again 
determined by Gibbs-Thompson equation, the same as equation (3.2). Whenever a 
particle nucleates, n* oligomers will be randomly selected in the simulation, and they are 
remove from the solution phase and assemble into the new particle.  
 The particle then grows if the solution is still supersaturated (C > C1*) or dissolves 
if the solution becomes undersaturated (C < C1*). For a bulk diffusion-limited system, the 
rates of particle growth and dissolution may be combined into a net particle growth rate 
as:  
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    1/31 0 1*p gR k x C C P x   (3.14) 
where kg0 is the particle growth constant and P(x) is the total number of particle with size 
x. As defined previously for the monodisperse system, x is the mass of the particle in 
terms of the number of monomers. In other works, the particle growth constant for the 
polydisperse systems is related to the diffusivity of each individual oligomer [158, 159], 
which is a function of the oligomer chain length. However in those cases, the 
supersaturation for the individual oligomer species would be used to calculate their 
individual particle growth rate, rather than the supersaturation based on the entire 
oligomer distribution. Hence, to be consistent with the previous assumption for particle 
nucleation, the supersaturation (C1*) based on the overall oligomer distribution is used, 
and all oligomers share the same particle growth constant (kg0), as shown in equation 
(3.14). Once the particle growth happens in the simulation, a random oligomer in the 
solution will be added into a chosen particle; the probably of a particle to be chosen is 
proportional to the particle size, x. 
 The assembly nucleation for a polydisperse system is more complicated than for a 
monodisperse system, as the numbers of different polymers is particle-wise. Hence, 
assembly nucleation rate for the i-th polymer in all particles is formulated as: 
  2p n q
q
R k P i  (3.15) 
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where kn is the assembly nucleation constant, Pq(i) is the number of the i-th polymer in a 
specific particle q. The assumption of the minimal size of assembly is again made here, 
and if Pq(i) < 2, that i-th polymer will not nucleate as the minimal size is two, as defined 
in Section 3.2.1. The assembly nucleus in the particle grows by consuming the other 
polymers with the same length, and is expressed as:  
    3p AG q q
q
R k A i P i  (3.16) 
where kAG is the growth constant and Aq(i) is the total number of i-th assemblies in the 
particle q. The assemblies are exposed to the solution phase and are considered as leaving 
the particles when their lengths are greater than the particle diameters (Lp), which is 
determined by equation (3.7). 
 Finally, the assembly growth (equation (3.17)) and dissolution (equation 3.18) 
rates for the i-th polymer assemblies are expressed as the following: 
  4 2p g i i
y
R k A y L  (3.17) 
 
   5 expp bp i i
y b





  (3.18) 
where kg is the assembly growth constant and kbp is the assembly dissolution constant in 
the solution. Ai(y) is the number of assemblies with y i-th polymers (assembly length = y), 
and Li is the concentration of the unassembled i-th polymer in solution. ΔG is the binding 
energy [150] between two monomers in the monomer assemblies. Here the binding 
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energy between assembled polymers is assumed to be a linear function of the length the 
polymers, and thus for an i-th mer the binding energy is i∆G [150, 160]. Bi(y) is the 
number of breakable bonds at the assembly ends. If y = 2, there is only one bond 
breakable and thus B = 1; if y > 2, both the bonds at the ends are breakable and B = 2. 
3.2.5 Simulation Results from the Polydisperse Model 
To simulate the phase transitions in the DCNs and to understand the interplay between 
the oligomer distribution (chemical distribution) and different physical phases (physical 
distribution), the peptide assembly model is extended with peptide oligomerization. The 
resulting model becomes capable of simulating a polydisperse system, which is similar to 
the polydisperse DCNs discussed in Chapter 2. Three key thermodynamic parameters are 
selected to probe the transitions and are sampled with Latin hypercube sampling: the 
oligomerization equilibrium constant (K1), the Flory-Huggins constant (χ), and the 
stacking energy for monomer (1-mer) assemblies (∆G). The oligomerization equilibrium 
constant, K1, is selected to test how the system would evolve with different oligomer 
bond strength and average oligomer chain length (j). Here the oligomerization rate 
constant, k1 in equation 3.11, is set in the fast limit to ensure that the oligomerization 
kinetics will not limit the change in chemical distribution, and the system reaches its 
thermodynamic state quickly.  For the other two parameters, both χ and ∆G have shown 
their impact on the final state of the monodisperse model; thus, they are selected again to 
investigate their impact on both the chemical and the physical distribution of the 
polydisperse system. The 500 parameter sets are constructed based upon these constants 
with Latin hypercube samplings, and the remaining parameters and constants are 
summarized in the following table: 
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Table 3.4  Summary of values for the polydisperse peptide assembly model. 
Parameter Description Units Value 
k1 Oligomerization rate constant mole-1 sec-1 42 10  
K1 
Oligomerization equilibrium 
constant – 5 × 10
4 - 100 × 104 
p1 Prefactor for particle nucleation rate L-1 sec-1 1013 
p2 Constant in the exponential part of 
the particle nucleation rate  
– 100 
mon Density of peptide g cm-3 1.4 
 Flory-Huggins parameter – 4 - 8 
Wmon Molecular weight of peptides g mole-1 410 
 Interfacial tension between peptide 
and solvent 
g s-2 15 
kb Boltzmann constant J K-1 231.38 10  
T Temperature K 300 
NA Avogadro’s number mole-1 236.023 10  
kg0 Kinetic constant for particle growth mole-1 sec-1 103 
kn Assembly nucleation constant sec-1 10-8 
kAG Assembly growth constant inside the 
particle 
sec-1 10-3 
par Particle density g cm-3 1.4 
kg Assembly growth constant in the 
solution phase 
mole-1 sec-1 102 
kbp Prefactor of Assembly dissolution sec-1 1010 
G Binding energy between peptides in 
the assembly 
J 10-19.7–10-18.5 
C0 Initial peptide concentration mM 1 
N Sample size – 52 10  
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 The same criteria used to classify the monodisperse model are used again here. 
Although these criteria do not characterize the chemical distribution of the results, they 
classify the final phase distribution (physical distribution) on the remaining physical 
phases. Here, the 500 parameter sets are sufficient to sample all six categories (Table 
3.5), with Figure 3.27 showing a representative example for each case. 
Table 3.5  Distribution of simulation results from the polydisperse model with 500 
parameter sets.  
Case Number of cases Percentage (%) 
1. Pure solution phase 4 0.8 
2. Pure assembly phase 211 42.2 
3. Solution-assembly equilibrium 31 6.2 
4. Solution-particle equilibrium 18 3.6 
5. Three-phase equilibrium 17 3.4 
6. Slow kinetics  219 43.8 
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Figure 3.27  Examples of the simulation results from the polydisperse peptide 
assembly model of (a) pure solution phase, (b) pure assembly phase, (c) solution-
assembly equilibrium, (d) solution-particle equilibrium, (e) three-phase equilibrium, 
and (f) slow kinetics. The parameters in Table 3.4 are used with: (a) K1 = 5.1 × 104, χ 
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= 4.63, and ΔG = 10-18.87 J, (b) K1 = 9.6 × 105, χ = 4.11, and ΔG = 10-18.75 J, (c) K1 = 3.6 
× 105, χ = 6.18, and ΔG = 10-19.16 J, (d) K1 = 6.7 × 105, χ = 7.04, and ΔG = 10-19.64 J, (e) 
K1 = 5.4 × 105, χ = 5.77, and ΔG = 10-19.6 J, (f) K1 = 6.3 × 105, χ = 5.71, and ΔG = 10-
19.61
 J 
 For a polydisperse system, the particle nucleation will not occur if the oligomers 
are soluble, due to short average oligomer length (j) or soluble building blocks with a low 
Flory-Huggins constant, as shown in Figure 3.28. For Case 1, the pure solution phase, the 
species undergo oligomerization but do not trigger the particle nucleation, as shown in 
Figure 3.27a and Figure 3.29; the species distribution (chemical distribution) reaches 
equilibrium within the first few hours, and all the oligomer concentrations remain 
constant without the perturbation of the other physical phases. On average, the Case 1 
results have the both the lowest oligomerization equilibrium constant (K1) (Figure 3.30) 
and the lowest Flory-Huggins constant (χ) (Figure 3.31); both of these parameters are 
critically tied the solubility for particles, as shown in equation (3.13) and Figure 3.28. If 
the 1-mer is less soluble and thus χ is high enough, even the 1-mers only are sufficient to 
nucleate the particle phase, as shown with the monodisperse model. If the oligomers 
grow steadily and thus K1 is large enough, particle nucleation would be triggered due to 
the long chain length. 
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Figure 3.28  Oligomer solubility for particle as a function of the average oligomer 
length and the Flory-Huggins constant (). The constants in Table 3.4 are used as 
the peptide properties and equation (3.19) is used to derive the solubility. 
 
Figure 3.29  Simulation results of the oligomer distribution when particle phase is 
not nucleated. The parameters used for this simulation are taken from Table 3.1 
with K1 = 5.1 × 104, χ = 4.63, and ΔG = 10-18.87 J. 
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Figure 3.30  Average oligomer equilibrium constant (K1) from the simulation 
results of the polydisperse model. The numbers in the parentheses are the number 
of results in each individual case. 
 
Figure 3.31  Average Flory-Huggins constant (χ) from the simulation results of the 
polydisperse model. The numbers in the parentheses are the number of results in 
each individual case. 
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 Although a smaller K1 is necessary to keep the oligomers soluble and thus to 
result in a pure solution phase, in other cases K1 does not impact the final physical 
distributions significantly. All the other cases have similar average K1 with similar large 
deviation, as shown in Figure 3.30. After particles nucleate in a solution, the phase 
distribution between the solution, particle and assembly phases is affected more by the 
Flory-Huggins constant χ (Figure 3.31) and the monomer assembly stacking energy ΔG 
(Figure 3.32). For example, when the assemblies are stable given a strong ΔG, the 
assembly dissolution becomes negligible and thus the assembly growth is almost 
irreversible. The stable assemblies then accumulate while all the other phases diminish, 
which results in the pure assembly phase (Case 2). 
 
Figure 3.32  Average stacking energy of monomer assembly (ΔG) from the 
simulation results of the polydisperse model. The numbers in the parentheses are 
the number of results in each individual case. 
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 The solution reaches the pure assembly phase (Case 2) when the oligomer 
assemblies become predominant while all the other phases disappear. As shown in Figure 
3.32, Case 2 on average has the highest stacking energy for monomer assembly (ΔG). 
The strong stacking energy (ΔG) makes the assemblies stable, and the assembly phase is 
dominated by the assemblies of shorter oligomers, which have the highest assembly 
mass. Here these assemblies with the highest mass are referred as the major products. Out 
of 211 results, the major product in Case 2 is either the 1-mer assembly (108 results) or 
the 2-mer assembly (103 results). Two representative examples are shown in Figure 3.33 
for the 1-mer and 2-mer assemblies as the major product. Other than these major 
products, multiple types of oligomer assemblies are observed in each individual 
simulation, as shown in Figure 3.33. Unlike the DCNs discussed in Chapter 2, which both 
yield 3-mer assemblies only, the coexistence of multiple types of assemblies suggests that 
there are other conditions to be considered to generate a predominant assembly. Also, in 
the Case 2 simulation results, there is no 3-mer assembly observed as the major product. 
The lack of 3-mer as the major product may be connected with the stable 1-mer and 2-




Figure 3.33  Simulation results of the oligomer distribution for the pure assembly 
phase. (a) The major product is 1-mer assembly. (b) The major product is 2-mer 
assembly. The parameters used for this simulation are taken from Table 3.1 with (a) 
K1 = 6.3 × 105, χ = 4.16, and ΔG = 10-18.65 J, and (b) K1 = 7.1 × 105, χ = 7.94, and ΔG = 
10-19.06 J. 
 Although 3-mer assembly is not the major product in any Case 2 results, it is 
selected in some of the Case 3 results, the solution-assembly equilibrium (Figure 3.27c). 
As shown in Figure 3.34 as a representative example, the 3-mer assembly is found as the 
major product when the solution and the assembly phase reach equilibrium (Figure 
3.34a), while other minor assembly products still present as well (Figure 3.34b and 
Figure 3.34c).  
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Figure 3.34  A representative simulation result for the solution-assembly 
equilibrium. The parameters used for this simulation are taken from Table 3.1 with 
K1 = 2.9 × 105, χ = 4.67, and ΔG = 10-19.06 J. (a) The distribution of molecules in the 
solution, particle, and assembly phases. (b) The overall oligomer distribution, (c) the 
oligomer distribution in the assembly phase, and (d) the oligomer distribution in the 
solution phase. 
 For Case 3, some results show solution-assembly equilibrium at the end time, but 
their chemical distributions are not stationary. In Figure 3.35 as a representative example, 
the overall oligomer concentration distribution has not stabilized after 500 hr (Figure 
3.35b), as the 1-mer assembly is dissolving (Figure 3.35c and Figure 3.35d). The 
dissolved 1-mer molecules do not accumulate in the solution phase, as the solution phase 
concentration does not change (Figure 3.35d). Rather, the 1-mer undergoes 
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oligomerization and then is consumed by other assemblies. This suggests that, for a 
polydisperse system, the equilibrium for the physical distribution (phase distribution) 
may not guarantee the equilibrium in the chemical distribution (the oligomer 
concentrations).  
 
Figure 3.35  A representative simulation result of solution-assembly equilibrium 
with stationary phase distribution but active oligomer exchange. The parameters 
used for this simulation are taken from Table 3.1 with K1 = 7.9 × 105, χ = 5.6, and ΔG 
= 10-18.90 J. (a) The distribution of molecules in the solution, particle, and assembly 
phases. (b) The overall oligomer distribution, (c) the oligomer distribution in the 
assembly phase, and (d) the oligomer distribution in the solution phase. 
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 For the monodisperse model, when the assemblies are not stable, they dissolve 
upon exposure to the solution, and remaining the solution phase and the particle phase 
reach equilibrium (Case 4). For this solution-particle equilibrium, the results on average 
have the highest Flory-Huggins constant (χ) to maintain the particle phase (Figure 3.31), 
while they have the lowest stacking energy for the assemblies to destabilize the 
assemblies (Figure 3.32).  
 Case 5 is the three-phase equilibrium, the coexistence of all solution, particle and 
assembly phases. Similar to the changing chemical distribution in Case 3, some results of 
Case 5 have not reached the steady state for the oligomer distribution (Figure 3.36a and 
Figure 3.36b). The assemblies of the shorter oligomers (1-mer, 2-mer or 3-mer) dissolve 
(Figure 3.36c), while the longer oligomers grow slowly due to the scarce free long 
oligomers (Figure 3.36d); oligomer breakage and incorporation into the particles may 
cause a low concentration for the longer oligomers, and thus delay the assembly growth. 
The slow assembly growth and the persistent particle and solution phases, together result 
in a three-phase coexistence. 
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Figure 3.36  A representative simulation result of three-phase equilibrium. The 
parameters used for this simulation are taken from Table 3.1 with K1 = 4.8 × 105, χ = 
7.1, and ΔG = 10-19.49 J. (a) The physical distribution of molecules in the solution, 
particle, and assembly phases. (b) The overall oligomer distribution, (c) the oligomer 
distribution in the assembly phase, and (d) the oligomer distribution in the solution 
phase. 
 The above discussion suggests that the steady state of the physical distribution 
may be achieved without the constant chemical distribution. However, for the slow 
kinetics (Case 6), some results show the opposite: the stationary chemical distribution 
with a changing physical distribution. Case 6 is classified as slow kinetics because its 
physical distribution is still changing after the reaction time (Figure 3.37). However, the 
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physical distribution may continue to change without further chemical exchange, as 
shown in Figure 3.37a and Figure 3.37b as a representative example. The dissolved 
oligomers from the particles do not undergo reversible oligomerization, but are 
incorporated into the assemblies directly.  
 
Figure 3.37  A representative simulation result of slow kinetics with constant 
chemical distribution. The parameters used for this simulation are taken from Table 
3.1 with K1 = 6.3 × 105, χ = 7.07, and ΔG = 10-18.50 J. (a) The physical distribution of 
molecules in the solution, particle, and assembly phases. (b) The overall oligomer 
distribution, (c) the oligomer distribution in the assembly phase, and (d) the 
oligomer distribution in the solution phase. 
 The above results suggest that, when the peptides are capable of both chemical 
exchange and physical transitions, the equilibrium of the chemical and the physical 
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distribution can be independent of each other (Figure 3.35 and Figure 3.37). The final 
state of the chemical distribution is summarized in Table 3.6 in terms of different 
physical states. The chemical distribution may achieve equilibrium when the assembly 
phase is stationary (Case 2 and Case 4), but the constant physical distribution may not 
guarantee a stationary chemical distribution (Case 3, 5, and 6). 
Table 3.6  The equilibrium of the chemical distribution as a function of the final 
physical distribution. Case 2 is pure assembly phase, Case 3 is solution-assembly 
equilibrium, Case 4 is solution-particle equilibrium, Case 5 is three-phase 
equilibrium, and Case 6 is slow kinetics. 
Chemical distribution Case 2 Case 3 Case 4 Case 5 Case 6 
In equilibrium 211 8 18 15 40 
Not in equilibrium 0 23 0 2 179 
Total 211 31 18 17 219 
 
 Also, for all of the results with assembly phase observed, they all contain multiple 
types of assemblies, which contradict with the experimental observation about the NF-
CHO and NFF-CHO DCNs. For both DCNs, only 3-mer (trimer) assemblies are 
observed, which suggests that the stacking energy of the oligomer assemblies may not be 
linear as assumed in equation (3.18) [161]. To reproduce the homogeneous 3-mer 
assemblies observed in the DCNs, the stacking energy (ΔG) for the 3-mer assembly is 
assumed to be stronger than that for the other assemblies, and thus only 3-mer assembly 
is stable enough to accumulate. As shown in Figure 3.38, the replication of 3-mer is 
achieved with the stable 3-mer assemblies, and the longer oligomers (4-mer and 5-mer) 
are absence after the 3-mer starts to accumulate, similar to the experimental results. 
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However, although the simulation shows that the system may be dominated by the 3-mer 
assemblies, why the 3-mer assemblies are more stable than the others remains to be 
clarified. One possibility is that  
 
Figure 3.38  Simulation results of 3-mer assemblies as the dominating product.  
The parameters used for this simulation are taken from Table 3.1 with K1 = 5 × 105, 
χ = 6, ΔG = 10-18.00 J for 3-mer and ΔG = 10-20.00 J for the rest oligomers. (a) The 
physical distribution of molecules in the solution, particle, and assembly phases. (b) 
The overall oligomer distribution, 
3.3 Conclusion 
A peptide assembly model using two-step nucleation is constructed to describe the 
maturation of assemblies via a metastable particle phase. The model predicts different 
phase transitions and equilibria are accessible by varying the Flory-Huggins parameter 
(), the particle growth constant (kg0), and the peptide stacking energy in the assemblies 
(G). The model shows that the solubilities for particles and assemblies, which are 
significantly influenced by  and G, determine the final thermodynamic states of the 
system. When the solubility of the particles is higher than that of assemblies, the particle 
phase dissolves while the assembly phase either dominates the system or exists in 
 96
equilibrium with free peptides. When the solubility of the assemblies is higher, the 
particle phase equilibrates with the solution phase and no assemblies are apparent. The 
final state of the system can therefore be rationally predicted given the values of the 
solubility of the particles and assemblies, but slow particle dissolution can delay 
maturation of the assembly phase.  
 This model was validated with A(16-22), the nucleation core of Amyloid  
peptide of Alzheimer’s disease, by evaluating assembly kinetics in solvents with different 
acetonitrile concentrations. TEM analyses show that the particle number increases and 
particle size decreases with decreasing acetonitrile concentration. Both TEM and CD data 
confirm that the kinetics of A(16-22) assembly are faster with increasing acetonitrile, 
while the solvent composition does not significantly impact the final equilibrium. The 
model predicts the more hydrophobic acetonitrile stabilizes the free A(16-22) peptides 
and increases its solubility of particles, which leaves more peptides for assembly growth 
and thus drives the reactions faster. These results can now be used to evaluate the 
assembly of more complex systems, such as recently published dynamic chemical 
networks that juxtapose chemical polymerization with physical phase transitions to create 
functional assemblies. 
 Finally, this model is extended for a polydisperse system with peptides able to 
perform oligomerization. The same six categories are considered, with 500 different 
parameter sets, which contain different values of oligomerization equilibrium constant 
(K1), Flory-Huggins constant (χ), and the stacking energy for the monomer assembly 
(ΔG). The simulation results show that, for the polydisperse system, the steady states of 
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the chemical and the physical distribution may be independent. Neither is a necessity for 
the other, and each could be achieved without the other. Also, none of the 500 results 
returns a single type dominating assembly. For the results with assemblies, they all 
contain multiple types of assemblies, and this is not consistent with the previous 
experimental observation for the DCNs. However, extra restriction on the stability of the 
assemblies may force the trimer assembly to dominate, as observed in the experimental 
system.  
3.4 Methods 
3.4.1 Monte Carlo Simulation Algorithm 
The kinetic Monte Carlo algorithm from Wang et al.[162] is used to follow the formation 
and size evolution of each individual particle and assembly, together with the peptide 
concentration in the solution phase. Rather than simulating the entire solution, only a 





  (3.11) 
where N is the number of peptides to be observed and C0 is the initial peptide 
concentration. The algorithm selects reactions to occur based on their individual 
stochastic rates, which are used to calculate the probabilities of the reactions. The 








  (3.12) 
where α(i) is determined as a function of the reaction order. For zeroth- and first-order 
reactions (R1, R3, R4, and R6) α(i) = 0, while for the second order reactions (R2 and R5) 
α(i) = 1. The individual probability (Pi) for the i-th reaction is then calculated based on 










Then, the next reaction, μ, is selected by a random number (q1) uniformly distributed 
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where q2 is another random number uniformly distributed between 0 and 1. Both q1 and 
q2 are sampled with the rand function in MATLAB with the current time as the seed. 
The execution of this Monte Carlo algorithm in MATLAB 2012a (The Mathworks, Inc) 
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follows Wang’s procedure [162], and the parameters and variables for equation (3.1) - 
(3.11) are listed in Table 3.1.  
3.4.2 Criteria to Classify the Simulation Results. 
The results from the Monte Carlo simulations are classified into different cases based on 
the remaining phases at the end. A set of criteria is established to categorize the results 
into different cases (Table 3.7). At the end time, a phase is considered as existing if it has 
a concentration greater than 1% of the total concentration, in order to ignore the 
misleading fluctuation of concentration associated with stochastic fluctuations. The 
concentration change for the last 5% of the reaction time (five hours) is used to define if 
multiple phases reach equilibrium with each other. The finite difference method is 
utilized to calculate the slopes of the concentration change with 0.05 hours as the 
interval:  






where Bj+1 and Bj are the peptide concentration in a phase at time tj+1 and tj, respectively. 
Here 1 0.05 hourj jt t t    .  
 The ttest function in MATLAB 2012a (The Mathworks, Inc) is carried out to 
check if the slopes have an average of 0. If the slope average is zero, the result is 
regarded as a stable equilibrium; otherwise the distribution is still changing and the 
kinetics are considered “slow,” as it is not finished with the reaction time. Table 3.7 
includes the final states and the criteria. 
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Table 3.7  Criteria to classify the simulation results. 
Cases Criteria 
1. Solution wins The maximal particle concentration remains 0 within the reaction time. 
2. Assembly wins  
The final solution and particle phase 
concentration are both less than 1% of the 
total concentration. 
3. Solution-assembly equilibrium 
The final solution and assembly phase are 
both above 1% of the total concentration. 
The final particle phase is less than 1% of the 
total concentration.  
The assembly concentration does not change 
for the last 5% of the reaction time. 
4. Solution-particle equilibrium 
The final solution and particle phase are both 
above 1% of the total concentration. 
The final assembly phase is less than 1% of 
the total concentration. 
The particle concentration does not change 
for the last 5% of the reaction time. 
5. Three-phase equilibrium 
All of the final solution, particle and 
assembly phase are above 1% of the total 
concentration. 
All concentration does not change for the last 
5% of the reaction time.  
6. Slow kinetics 
Either solution phase and/or particle phase 
are above 1% of the total concentration. 
Concentrations are still changing within the 
last 5% of the reaction time. 
 
3.4.3 A(16-22) Solution Preparation 
A(16-22) peptides are synthesized using solid phase peptide synthesis, and the synthetic 
products are purified with high-performance liquid chromatography (HPLC), using a 
water/acetonitrile gradient with 0.1% trifluoroacetic acid in a C-18 reverse phase column 
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[21]. After lyophilization, the purified peptide is stored at -20 oC for later use. To 
disassemble the preexisting assemblies, the peptide powder is dissolved in 
hexafluoroisopropanol (HFIP) to a concentration of 1 mg/mL and the mixture is 
sonicated for 2 hours in a bath sonicator. HFIP is removed with a Labconco CentriVap 
Concentrator-7970010, and the resulting peptide film is placed in a desiccator overnight 
to remove the remaining HFIP. Immediately prior to conducting an assembly experiment, 
the peptide film is suspended with HFIP and sonicated for 15 minutes. The sonicated 
solution is diluted with 40%, 60% or 80% (v:v) acetonitrile in water, to obtain a final 
HFIP concentration of 1% by volume with the desired peptide concentration. The peptide 
solution is incubated at 22 oC and aliquots of the solution are removed at predetermined 
times for measurement of assembly kinetics. 
3.4.4 Kinetics of A(16-22) Assembly Measured with CD, TEM and FTIR 
Circular dichroism (CD) is used extensively to determine -sheet content of the peptide 
solutions. Here a volume of 23 μL of peptide solution is loaded into a demountable 
window cell with a 0.1 mm path length. The ellipticity is obtained at wavelengths from 
185–260 nm under a resolution of 0.2 nm with a bandwidth of 2 nm at a scanning rate of 
200 nm/min using a Jasco J-810 spectropolarimeter. After background correction, the 
spectrum from the average of three scans is saved and the resulting ellipticity at 217 nm 
is used as the indicator of -sheet content.   
 The morphologies of the particles and assemblies are observed with transmission 
electron microscopy (TEM). To deposit the assemblies and particles onto the grid, the 
peptide solution is loaded onto the copper grid for one min, and the excess peptide 
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solution is wicked away with filter paper. The resulting grid is negatively stained with 
1.5-wt % methylamine tungstate solution for three minutes before the stain solution is 
wicked away with filter paper. The grid is then stored in a vacuum desiccator overnight to 
remove the remaining liquid. TEM images are recorded with a Hitachi H-7500 
transmission electron microscope. The particle size distribution is obtained by analyzing 
the TEM images with ImageJ 1.48v (National Institutes of Health, USA). 
 Once the A(16-22) assemblies are matured and the CD signatures of the solution 
do not change significantly with time, FTIR is used to probe the final peptide strand 
arrangement. Peptide solutions with a volume of 8 μL are loaded onto the diamond chip 
of a JASCO FT/IR-4100. The absorbance spectra are recorded against a background 




CHAPTER 4.  
KINETIC AND STRUCTURAL EVOLUTION OF PH-SENSITIVE 
PEPTIDE ASSEMBLIES 
4.1 Introduction 
In the last chapter, Aβ(16-22) is studied as the model for the kinetics of peptide assembly 
with two-step nucleation. In this chapter, the assembly of Aβ(16-22) is investigated 
further. The assemblies of Aβ(16-22) are pH-sensitive. At neutral pH, the Aβ(16-22) 
peptides assemble into solid fibers (Figure 4.1a) with an antiparallel in-register β-sheet 
structure [21, 155] (Figure 4.1b, c). The glutamic acid (E22) at the C-terminus bears a 
negative charge and forms a cross-strand salt bridge with the positively-charged lysine 
residue (K16). However, if the pH value is below the pKa of glutamic acid, it loses its 
negative charge and thus the salt bridge as well. Aβ(16-22) then assembles into hollow 
nanotubes (Figure 4.1d) with an antiparallel out-of-register β-sheet structure (Figure 4.1e) 
[21, 155]. Without the salt bridges, the out-of-register structure is stabilized by the stereo 
preference of the bulky valine side chain cross-strand paired with the less bulky alanine 
[155, 163] (Figure 4.1f). 
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Figure 4.1  Assembly of Aβ(16-22) at neutral and acidic pH. At neutral pH, Aβ(16-
22) assembles into (a) solid fibers with an (b) antiparallel in-register β-sheet with 
side-chain stacking shown in (c). At acidic pH, Aβ(16-22) assembles into (d) hollow 
tubes with an (e) antiparallel out-of-register β-sheet with side-chain stacking shown 
in (f). Scale bar = 200 nm. 
 Although the structure of Aβ(16-22) assemblies have been widely-studied [164], 
the assembly kinetics of Aβ(16-22), especially at acidic pH, have not been clearly 
elucidated [77]. The critical nucleation events of Aβ(16-22) assembly have been 
computationally simulated [1, 5, 165-167], but these simulations are focused on the early 
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stage of the assembly process. Experimentally, Nilsson et al. measured the kinetics of 
Aβ(16-22) assembly with HPLC, while they did not provide enough microscope images 
to morphologically explain the possible topology transitions from the possible 
intermediates to the final products [168]. In Ref. [21] it is shown that the assemblies of 
Aβ(16-22) emerged from the particle phase, and thus the kinetics follow a two-step 
nucleation mechanism [64, 169]. Lin and coworkers incubated Aβ(16-22) in phosphate-
buffered saline (PBS) to probe its assembly kinetics [77]. Before the Aβ(16-22) fibers 
arise from metastable particles, a flake-like side product is observed first. As revealed by 
in situ atomic force microscopy (AFM), the flakes are metastable and dissolve as the 
fibers mature. However, in this study the coupling registry of the assembled peptides, 
which influences the stability and the morphology of the assemblies [45, 60], is not 
followed with instruments like FTIR nor NMR. Also, none of the above experimental 
works report the assembly process at acidic pH, and kinetics of Aβ(16-22) assembly at 
acidic pH, which leads to the nanotube structures, have not been demonstrated yet.  
 Here we report the assembly kinetics of isotope-edited Aβ(16-22), [1-13C]F19 
Aβ(16-22), at both neutral and acidic pH to elucidate whether the reaction pathways are 
pH-dependent. To investigate the possible intermediates and the degree of assembly 
maturation, circular dichroism (CD) is utilized to probe the β-sheet content, and 
transmission electron microscopy (TEM) is used to observe the morphologies of the 
assemblies. In addition, isotope-edited FTIR analyses are performed to follow the 
reaction pathways and the structural transitions by elucidating the registry populations of 
the assembled peptides [45]. Combined together, these techniques show that at both 
neutral and acidic pH, [1-13C]F19 Aβ(16-22) forms the same ribbon intermediates, while 
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the ribbons undergo different reaction pathways in the solution which lead to different 
final macrostructures.  
4.2 Results and Discussion 
4.2.1 Development of the IR Basis Sets  
The IR basis set necessary for registry analysis is obtained with [1-13C]F19 Aβ(16-22) 
solutions independent from those for kinetic measurements. Compared to the other 
residues, the residue F19 of Aβ(16-22) is chosen for 13C-enrichment because it provides 
the most significant difference in IR bands between different registries [155]; these 
registries have been previously defined by solid state NMR as antiparallel in-register β-
sheet at neutral pH and out-of-register β-sheet at acidic pH [155]. To obtain the IR 
signatures of the in-register and out-of-register structures, [1-13C]F19 Aβ(16-22) 
solutions with a concentration of 1.0 mM are incubated at neutral and acidic pH, 
respectively. Their IR spectra are assigned as the basis set after the spectra remain 
constant for at least one month, as shown in Figure 4.2.  
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Figure 4.2  The IR basis set for spectrum deconvolution. For parallel β-sheet 
signature (black), the spectrum is obtained with [1-13C]F19 Aβ(16-22)E22Q 
assemblies [60]. The antiparallel in-register β-sheet signature (red) is obtained from 
[1-13C]F19 Aβ(16-22) assemblies incubated at neutral pH, while the antiparallel out-
of-register signature (green) comes from the same peptide incubated at acidic pH. 
The [1-13C]F19 Aβ(16-22) peptide is dissolved in HFIP to disassemble the possible 
assemblies, resulting in the unassembled peptide signature (blue) [60].  
 The maturation of these assembly morphologies is further confirmed by TEM 
images (Figure 4.3). The images are obtained after the IR spectra of the peptide solution 
remain constant for more than a month. As shown in Figure 4.3, [1-13C]F19 Aβ(16-22) 
assembles into fibers at neutral pH and tubes at acidic pH. However, particles are 
observed along with these assemblies, independent of pH. As the particle phase may 
contribute to IR absorbance, experiments have been carried out to obtain the IR signature 
of the pure particle phase for basis set development. To decrease the supersaturation and 
thus exclude the possible assemblies, fresh [1-13C]F19 Aβ(16-22) solution is incubated 
with increased temperature, different acetonitrile concentrations, and/or a lower peptide 
concentration. However, assemblies are always observed together with the particles by 
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TEM images, and thus currently the IR basis set for the pure particle phase is not 
available yet. As the particles may not be as ordered as the assemblies, the contribution of 
the particle phase to the IR spectra is assumed to be similar to the unassembled peptides 
(Figure 4.2, blue line). The spectrum deconvolution is then used to focus on the registry 
analysis between the assemblies. Also, to make the basis set robust enough to analyze 
other possible structures, the parallel β-sheet signature from [1-13C]F19 Aβ(16-22)E22Q 
(Figure 4.2, black line) and the unassembled peptide signature from [1-13C]F19 Aβ(16-
22) (Figure 4.2, blue line) are obtained from Ref. [60]. It should be noticed that, in Ref. 
[60], [1-13C]F19 Aβ(16-22)E22Q also forms a particle-assembly equilibrium at the end of 
the incubation, which is similar to the final state of [1-13C]F19 Aβ(16-22) assembly. 
 
Figure 4.3  TEM images of 1.0 mM [1-13C]F19 Aβ(16-22) solutions after the IR 
signature becomes stable at (left) neutral pH and (right) acidic pH. Scale bar = 200 
nm. 
4.2.2 Morphological evolution of [1-13C]F19 Aβ(16-22) Assembly 
A series of TEM images reports the morphological changes of the [1-13C]F19 Aβ(16-22) 
assemblies at acidic pH and neutral pH. As shown in Figure 4.4 and Figure 4.5, the 
assembly of [1-13C]F19 Aβ(16-22) is pH-responsive, acidic conditions giving hollow 
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nanotubes and neutral conditions giving fibers [164, 170-173]. Despite this 
morphological difference, the pathway appears remarkably similar. After one hour of 
incubation, the ribbons are formed together with the particles at both pH (Figure 4.4a and 
Figure 4.5a), while they are the metastable products which diminish during the 
incubation. At the acidic pH, the ribbons are the on-pathway intermediates; after they 
grow longer and wider, they mature into the tube morphology [21, 174] (Figure 4.4b and 
c). At neutral pH the fibers and the particles grow with the amount of ribbons diminishing 
(Figure 4.5b and c). After the ribbons disappear, the particles, which are a constant phase 
throughout the incubation, coexist and equilibrate with either the tubes at acidic pH 
(Figure 4.4d) and the fiber at the neutral pH (Figure 4.5d). The final morphology 
difference between fibers and tubes is the result of fibers containing antiparallel in-
register β-sheets (Figure 4.1b and c), while the hollow nanotubes contain antiparallel β-




Figure 4.4  TEM images of 1.0 mM [1-13C]F19 Aβ(16-22) solution at neutral pH 
after incubation for (a) 1 hr, (b) 7 days, (c) 10 days, and (d) 14 days. Scale bar = 200 
nm. 
 
Figure 4.5  TEM images of 1.0 mM [1-13C]F19 Aβ(16-22) solution at neutral pH 
after incubation for (a) 1 hr, (b) 1 day, (c) 3 days, and (d) 9 days.  
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4.2.3 Maturation of  [1-13C]F19 Aβ(16-22) assemblies probed by CD 
CD follows the growth of the β-sheet content. At neutral pH (Figure 4.7, black) the 
acquired ellipticity is much weaker [175] but the β-sheet signature develops immediately 
and plateaus after day five, consistent with TEM-determined maturation (Figure 4.5). In 
contrast, at acidic pH the negative ellipticity at 217 nm appears insensitive to the ribbons 
(Figure 4.6a and Figure 4.7, blue). To test CD’s capability of detecting Aβ(16-22) 
ribbons, Aβ(16-22) solution is prepared at acidic pH with a lower peptide concentration 
(0.5 mM), where the ribbons accumulate (Figure 4.8) while they remain insensitive to CD 
(Figure 4.9). Although CD cannot probe the ribbons at the early time points, the β-sheet 
content at acidic pH grows as the intermediate ribbons transition into tubes (Figure 4.7, 
blue). After two days, the negative ellipticity establishes and plateaus after twelve days 
(Figure 4.7, blue), again consistent with the time dependence obtained with TEM images 




Figure 4.6  CD spectrum of 1 mM [1-13C]F19 Aβ(16-22) solution in 40% 
Acetonitrile at (a) acidic pH and (b) neutral pH as a function of time. The negative 
signature develops as the β-sheet concentration increases. The intensity at 217 nm 
becomes an indicator of the degree of self-assembly. 
 
Figure 4.7  Ellipticity at 217 nm measured by CD for 1 mM [1-13C]F19 Aβ(16-22) 
solution in 40% acetonitrile under (blue, right y-axis) acidic pH and (black, left y-




Figure 4.8  TEM images of 0.5 mM Aβ(16-22) at acidic pH after (a) 0 hr, (b) 1 day 
and (c) 8 days.  
 
Figure 4.9  The CD spectra of 0.5 mM Aβ(16-22) at acidic pH. 
4.2.4 Isotope-edited IR Analyses for Registry Transition  
Isotope-edited FTIR is applied to reveal the coupling between the assembled [1-13C]F19 
Aβ(16-22) peptides. With the 13C-enrichment, the [1-13C]F19 Aβ(16-22) assembly shows 
a 12C peak around 1638 cm-1 and a 13C peak around 1597 cm-1 (Figure 4.10); for better 
comparison, the IR spectrum is normalized based on the height of the 12C peak [45, 60]. 
To detect the possible transition of the inter-strand coupling of the assembled peptides 
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[45, 60, 155], these IR spectra are scaled with the basis set from the matured assemblies 
(Figure 4.2), and are represented in terms of the scaling coefficients as shown in Figure 
4.11. 
 
Figure 4.10  IR spectra of 1 mM [1-13C]F19 Aβ(16-22) solution in 40% Acetonitrile 
at (a) acidic pH and (b) neutral pH. 
 The anti-parallel out-of-register -sheets signature dominates immediately under 
both acidic and neutral conditions (Figure 4.11), consistent with the ribbons existing as 
independent of pH (Figure 4.4a and Figure 4.5a). At acidic pH, the ribbons transition to 
the nanotubes without changing peptide registry; as the morphological change (Figure 
4.4) does not affect the peptide registry, the ribbons are the on-pathway intermediates for 
the tubes. The minor in-register β-sheet component in Figure 4.11a at the early time 
points imply that the registry may still be flexible and the out-of-register structure is not 
entirely matured yet (Figure 4.11a). These minor components decreases after the most 
stable out-of-register structure predominate after day 12, on which all the ribbons 
disappear by TEM images (Figure 4.4). 
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Figure 4.11  Fits of IR spectra of [1-13C]F19 Aβ(16-22) under (a) acidic pH and (b) 
neutral pH. The kinetic IR spectra of [1-13C]F19 Aβ(16-22) solution are fitted by the 
basis set in Figure S3 to reveal any possible registry transition. 
 Although it is incapable of distinguishing the intermediates and final products at 
acidic pH, at neutral pH IR probes the transition from the intermediate ribbons to final 
fibers (Figure 4.10b and Figure 4.11b). The initial antiparallel out-of-register β-sheet 
structure suggests the same ribbon intermediates are formed pH-independently. However, 
at neutral pH this initial IR signature does not remain constant, but slowly transitions into 
the in-register β-sheet signature. The registry transition continues for 14 days, while the 
CD intensity stops changing on day nine. The inconsistent paces may come from the slow 
coupling maturation compared to the fiber growth. After the peptides assemble into fibers 
with the β-sheet structure, the coupling between the peptides may not be stabilized with 
the in-register structure yet. The flexible couplings then contribute to other structures 
such as out-of-register β-sheet, before the fibers eventually anneal into the stable form. 
Thus, the IR transition continues until the assembled peptides mature with the stable in-
register structure at neutral pH, as observed in Figure 4.11b. 
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 Combined together, the kinetics and the structural evolution of [1-13C]F19 Aβ(16-
22) assembly are revealed. The peptide initially assembles into ribbons at both acidic and 
neutral pH, which later mature into the final tubes or fibers. Also, IR, CD and TEM are 
all necessary to provide this comprehensive understanding. The IR probes the peptide 
coupling patterns, the TEM images reveal the morphological transition, while CD 
measures the maturation of the assemblies.  
4.2.5 Compare the Assembly Pathway of Aβ(16-22) at Neutral and Acidic pH  
The kinetics of Aβ(16-22) assembly at both neutral and acidic pH is measured to probe 
the possible pH-dependent assembly pathway. Through two-step nucleation, the 
nucleation and growth environments are different yet essential for assembly 
development. It has been shown that the Aβ(16-22) peptide assemblies nucleate inside 
the particles, while they mature in the solution [21, 63, 77]. The environmental difference 
between the particle and the solution phases may impact the transition between different 
assembly morphologies [21].  
 Independent of pH, Aβ(16-22) initially forms metastable ribbons which are 
intermediates with antiparallel out-of-register β-sheet structure. The Dutch congener of 
Aβ(16-22), E22Q, forms antiparallel out-of-register β-sheet ribbons as well, which  
transition to fibers with parallel in-register β-sheet structure [60]. The common ribbon 
morphology with the same out-of-register structure suggest that A(16-22) and E22Q 
share the similar and pH-independent environment (particles) for ribbon nucleation. As 
the out-of-register coupling is driven by the stereo preference (Figure 4.1), the formation 
of Aβ(16-22) ribbons at neutral pH suggests that the particle environment may have 
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affected the pKa of the peptide residues, and the charges of either K16 and E22 may 
become weakened. As a result, Aβ(16-22) forms out-of-register ribbons as it does not 
access the salt bridge even at neutral pH, the same intermediate structure for E22Q and 
Aβ(16-22) at acidic pH, both of which cannot access inter-strand salt bridges to stabilize 
the structure. Although the properties of the particles remain to be elucidated, the above 
results show that the E22Q and Aβ(16-22) particles are probably similar and are not 
affected by different pH conditions.  
 Although formed independent of pH, the metastable ribbon intermediates undergo 
pH-dependent reaction pathways for the final product maturation. At the acidic pH, the 
ribbons are the on-pathway intermediates as they transform themselves into tubes. 
Because the out-of-register β-sheet is stable at acidic pH, the tubes keep the registry from 
the intermediate ribbons. However, at neutral pH, the fibers do not inherit the same 
registry from ribbons, as their in-register structure is more stable at neutral pH. The 
ribbons disappear and the fibers mature after one week of incubation, based on the CD 
(Figure 4.6) and TEM observation (Figure 4.5). The mechanism underlying the registry 
shift is not defined. One possible mechanism would require two separate nuclei in the 
particle; the in-register fibers nucleate more slowly, and after they emerge into the 
solution, the out-of-register ribbons dissolve and the released peptides sequestered into 
the more stable fibers. 
 Another possible mechanism, more consistent with the autocatalytic growth of the 
E22Q fiber in solution, is that the out-of-register structure templates an in-register 
conformational mutation. The dock-and-lock models for propagation at the ends of the 
assemblies [176] could then fix an incoming strand so the cross-strand salt bridge directs 
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the locking of the new strand and stabilize it. The multi-stage assembly pathway then 
diversifies the environmental context as well as the range of structures available to 
amyloid assembly, and raises fundamental questions about the nature of the particle 
phase. 
4.3 Conclusion 
In this study we combined isotope-edited IR, CD, and TEM to analyze the kinetics of 
Aβ(16-22) assembly at acidic and neutral pH. At both pH conditions, the same ribbon 
intermediates with out-of-register anti-parallel β-sheet are detected. This implies that the 
ribbon nucleation environments, the particles, of Aβ(16-22) are similar and not pH-
dependent. However, the ribbons undergo different reaction pathways for assembly 
maturation under neutral and acidic pH conditions. At neutral pH, the out-of-register 
ribbons are less stable than the in-register fibers as the latter are stabilized with the salt 
bridges between the lysine and glutamic acid residues. The out-of-register ribbons 
disappear as the fibers grow and mature. At acidic pH, since the out-of-register coupling 
is stable, the ribbons are the on-pathway intermediates, which wrap themselves into the 
final tube structures. 
 This is the first study reporting the kinetics of Aβ(16-22) assembly at acidic pH. 
Combined together, the structural transition analyzed with the deconvolution of IR 
spectra, the morphologies of the assemblies recorded by TEM, and the beta-sheet content 
measured by CD, make it possible to follow the transition of the peptide assembly 
process from the molecular level to the macrostructural level. The methodology used and 
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the assembly mechanism revealed in this study may extend disease therapy design and 
novel material construction.  
4.4 Methods 
4.4.1 Peptide Solution Preparation 
The [1-13C]F19 Aβ(16-22) peptides are synthesized using the F-MOC protected natural 
abundance and the [1-13C]F19-enriched amino acids with solid state peptide synthesis 
[21, 45, 60]. The synthetic peptides are purified with high-performance liquid 
chromatography (HPLC), in a C-18 reverse phase column with a water/acetonitrile 
gradient with 0.1% trifluoroacetic acid (TFA). The peptide solution from HPLC then 
undergoes lyophilization and the resulting peptide powder is stored under -20 oC before 
use. 
To prepare the peptide solution for the kinetic measurements, the peptides are 
dissolved in hexafluoroisopropanol (HFIP) before sonication for two hours. HFIP is then 
evaporated with a Labconco CentriVap Concentrator-7970010, and the resulting peptide 
film is placed in a desiccator overnight to remove residual HFIP. To assemble the 
peptides at neutral pH, the disaggregated peptides are suspended again with HFIP, and 
sonicated for 15 min. The peptides in HFIP are then diluted with 40% (v:v) acetonitrile in 
water to obtain a final HFIP concentration of 1% by volume and the desired peptide 
concentration. For acidic solution, 40% acetonitrile with 0.1% TFA is used instead of 
pure 40% acetonitrile to dilute the suspended peptides in HFIP. The peptide solution is 
then incubated at 22 oC and aliquots of the solution are removed at predetermined time 
points for kinetic measurements.  
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4.4.2 Transmission Electron Microscopy (TEM) 
The topologies of the peptide assemblies are reported with transmission electron 
microscopy (TEM). First, three water drops with an individual volume of 100 μL are 
loaded onto a piece of parafilm for sample dilution. Then, 5 μL of peptide solution is 
loaded onto the copper grid for one minute to deposit the assemblies. After one minute of 
deposition, the grid is put upside down to let the peptide solution contact the three water 
drops in sequence, which dilutes the peptide solution and washes away access assemblies. 
The diluted peptide solution on the grid is wicked away with a piece of filter paper and 
the grid is negatively stained with 1.5-wt % methylamine tungstate solution for 30 
seconds. The stain solution is wicked away with filter paper and the grid is placed in a 
vacuum desiccator to dry overnight. TEM images are recorded with a Hitachi H-7500 
transmission electron microscope. 
4.4.3 Circular Dichroism (CD) 
The β-sheet content of the peptide solution is probed by circular dichroism (CD). CD 
measurement is performed with 23 μL peptide solution in a demountable window cell 
with a 0.1 mm path length. The spectrum is recorded using a Jasco J-810 
spectropolarimeter with wavelengths from 185–260 nm, a resolution of 0.2 nm, a 
bandwidth of 2 nm, and a scanning rate of 200 nm per min. After background correction, 
the average of three consecutive scans is saved and the ellipticity at 217 nm is used to 
quantify the β-sheet content of the peptide solution. 
4.4.4 Attenuated Total Reflectance Fourier Transform Infrared (FTIR) 
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The coupling of the assembled peptides is measured with isotope-edited FTIR to identify 
the registry. Eight μL of the peptide solution is loaded onto the diamond chip of a JASCO 
FT/IR-4100. After the sample dries down, the IR absorbance of the sample is recorded 
against a background spectrum at a wavenumber range of 1000 to 3600 cm-1 at room 
temperature. The average of 250 consecutive scans is saved and the spectrum is 
normalized to the peak height of the 12C band.  
An IR basis set is established to probe the structural transition of the assemblies 
with spectrum deconvolution. The registries of matured Aβ(16-22) assemblies have been 
previously defined by solid state NMR as antiparallel in-registry at neutral pH and out-of-
registry at acidic pH [155]. Peptide solutions, independent from those for kinetic 
measurements, are incubated at either neutral or acidic pH as described in Section 2.1. 
Their spectra are assigned as the basis set for their corresponding registries after the 
spectra remain constant for more than a month, when the assembly structure does not 
change significantly. For spectrum deconvolution with the basis set, the kinetic IR spectra 
with the range from 1575 cm-1 to 1725 cm-1 are analyzed as the linear combination of the 







CHAPTER 5.  
CATALYTIC FUNCTION OF PEPTIDE ASSEMBLIES 
5.1 Introduction 
Protein enzymes catalyze diverse reactions in aqueous environments with high selectivity 
[24] and yield [23], and their outstanding catalytic ability inspires researchers to construct 
and design artificial enzymes. However, the complex protein folding mechanism has 
hindered the development of amino acid-based catalysts, as misfolded and unfolded 
proteins do not access the correct active sites for reactions.  
 On the other hand, similar to protein folding for ordered structures, peptide 
assembly has become an attractive bottom-up method to make catalysts, because solving 
the protein folding problem is not required [177]. Here we construct and investigate 
peptide assemblies that are able to catalyze specific enantioselective chemical reactions. 
The catalytic strength of these assemblies is rationally adjusted by engineering the 
structure of individual amino acid residues. The size of the binding pocket and 
enantioselectivity are analyzed with a modified Michaelis-Menten mechanism [178, 179], 
which also reveals the physical properties of these peptide assemblies. Combined 
together, the experimental and modeling results help to unveil the catalytic nature of 
these peptide assemblies.  
5.2 Results and Discussion 
5.2.1 The Catalytic Activity from the Assemblies of Ac-KLVFFAE-NH2 and its Analogs 
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The reactive residues on the assembly surface may have catalytic potential. For Ac-
KLVFFAE-NH2 (A(16-22)) and its analogs, the amine groups on the lysine residues 
(K16) may be catalytic for amine-driven reactions [180]. To test the catalytic ability of 
these peptide assemblies, here methodol (4-hydroxy-4-(6-methoxy-2-naphthyl)-2-
butanone) is selected as the substrate, which undergoes retro-aldol catalysis [181] and has 
been applied in several catalytic systems [182-184]. As shown in Figure 5.1 [180], 
methodol is cleaved into an acetone and a fluorescent aldehyde (6-methoxy-2-
naphthaldehyde), the latter of which may be quantified with fluorescence to report the 
reaction progress.  
 
Figure 5.1  Retro-aldol reaction of methodol (4-hydroxy-4-(6-methoxy-2-naphthyl)-





 Several assemblies of the Ac-KLVFFAE-NH2 analogs are mixed with methodol 
to test their catalytic capability. Figure 5.2 summarizes the initial rates from these peptide 
assemblies, including both solid fibers and hollow tubes. The Ac-KLVFFAE-NH2 fiber is 
inactive toward the methodol substrate and does not cleave the methodol substrate. As the 
electrostatic interaction between the positive lysine and negative glutamic acid residues 
may affect the catalytic ability of the assemblies, this salt bridge is removed by replacing 
the glutamic acid with the neutral glutamine (Q). This glutamine analog, Ac-KLVFFAQ-
NH2, assembles into fibers as well, but it does not cleave the methodol substrate (Figure 
5.2). On the other hand, the E22L analog, Ac-KLVFFAL-NH2, is able to cleave the 
methodol substrate (Figure 5.2). Ac-KLVFFAL-NH2 assembles into tube with anti-
parallel -sheet structure [185], and the flexible lysine residues on the tube surface 
provide a range of possible docking modes for methodol (Figure 5.3).  
 Not all peptide tubes are catalytically functional, and the microenvironment in the 
binding sites is crucial for methodol cleavage. When the valine (V18) in Ac-KLVFFAE-
NH2 is replaced with tert-leucine (ter-L), the Ac-KL(ter-L)FFAE-NH2 peptide assembles 
into tubes with the surface similar to that of Ac-KLVFFAL-NH2 [163]; however the 
negatively charged glutamic acid in Ac-KL(ter-L)FFAE-NH2 assemblies limits the 
catalytic efficiency for methodol cleavage, as shown in Figure 5.2. No retro-aldol 
catalysis is detected for Ac-KL(ter-L)FFAQ-NH2 either, which is the Q analog of Ac-
KL(ter-L)FFAE-NH2. Ac-KL(ter-L)FFAQ-NH2, Ac-KL(ter-L)FFAE-NH2, and Ac-
KLVFFAL-NH2 peptides all have the amine groups on the lysine side chains, but they are 
all catalytically inactive. This suggests that the possible free peptides in these systems 
cannot cleave the substrate, and the catalytic activity from the Ac-KLVFFAL-NH2 tubes 
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is associated with the binding pocket only. Otherwise, Ac-KL(ter-L)FFAQ-NH2 and Ac-
KL(ter-L)FFAE-NH2 would have shown catalytic ability as well, given the free peptides. 
Finally, to highlight the important primary amine for the catalysis, the lysine (K16) in 
Ac-KLVFFAL-NH2 is replaced with arginine (R), which does not have the primary 
amine group for retro-aldol reaction. As shown in Figure 5.2, the Ac-RLVFFAL-NH2 
tubes are not able to perform methodol cleavage, indicating the importance of the primary 
amine group on the lysine side chain. 
 
Figure 5.2  Initial rate of production of 6-methoxy-2-naphthaldehyde from 80 μM 
()-methodol with the assemblies of 500 μM Ac-KLVFFAE-NH2 and its analogs. 




Figure 5.3  Docking of methodol onto the KLVFFAL tube surface. (a) Molecular 
dynamics simulation of S-methodol docking onto the surface of KLVFFAL anti-
parallel out-of-register amyloid assembly. The lysine residues are colored blue, 
LVFFAL residues are colored grey, and the methodol substrates are drawn as sticks 
with carbons colored green, oxygen red and hydrogen white. (b, c) Expansions of 
methodol (space filling) on tube surface with peptides drawn as sticks. Image and 
data adapted from Ref. [186] with permission.  
 The catalytic efficiency of the Ac-KLVFFAL-NH2 tubes is rationally adjusted by 
modifying the reactive amine group. The distance of the amine groups from the surface 
may be crucial to improve the catalytic efficiency; if the amine groups are closer to the 
tube surface, the substrates may react with the amine groups more efficiently. To test this 
hypothesis, the amine tether of the lysine residue is shortened by replacing lysine with 
ornithine and -alanine (Figure 5.4). As shown in Figure 5.2, the catalytic efficiency is 
raised when the amine group becomes closer to the tube surface, as Ac-OrnLVFFAL-
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NH2 and AlaLVFFAL-NH2 break the methodol more quickly than the Ac-KLVFFAL-
NH2 does. 
 
Figure 5.4  Catalytic amine groups for retro-aldol reaction from (a) Ac-
KLVFFAL-NH2, (b) Ac-OrnLVFFAL-NH2, and (c) βAlaLVFFAL-NH2 tubes. The 
catalytic amine groups are highlighted in bold and italic. The R group represents 
the LVFFAL-NH2 group. 
 Together with the Ac-KLVFFAL-NH2 tubes, the Ac-OrnLVFFAL-NH2 and the 
AlaLVFFAL-NH2 tubes have shown catalytic capability, and the catalytic efficiency is 
enhanced when the primary amine group is closer to the tube surface (Figure 5.2). 
However, as the AlaLVFFAL-NH2 tubes are not stable and transition into ribbons after 
several days under the reaction condition, the following kinetic analyses are focused on 
the Ac-KLVFFAL-NH2 and the Ac-OrnLVFFAL-NH2 tubes. 
5.2.2 Retro-aldol kinetics for the peptide assemblies 
To investigate the retro-aldol kinetics of the peptide assemblies in details, 500 μM 
assembled peptides are mixed with 76.7 μM racemic methodol solution, which contains 
equal R- and S-methodol; the unreacted R- and S-methodol concentration is determined 
with chiral HPLC and the concentration of the aldehyde product (6-methoxy-2-
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naphthaldehyde) is determined by fluorescence. The kinetic analysis of Ac-KLVFFAL-
NH2 and Ac-OrnLVFFAL-NH2 tubes is shown in Figure 5.5.  
 
 
Figure 5.5  The progress of retro-aldol reaction for methodol with Ac-KLVFFAL-
NH2 and Ac-OrnLVFFAL-NH2 tubes. (a) Chiral HPLC of 500 µM peptide and 76.7 
µM racemic methodol. (b) Naphthaldehyde fluorescence of 500 µM peptides with 
76.7 M racemic methodol. Data adapted from Ref. [187]. Error bars are included 
with size similar to the data points. 
The chiral HPLC measures the racemic substrate consumption, which provides 
the catalytic efficiency and the selectivity of the peptide assemblies. Figure 5.5a shows 
that both the Ac-KLVFFAL-NH2 and Ac-OrnLVFFAL-NH2 tubes enantioselectively 
cleave the racemic methodol: both tubes have a higher conversion rate for S- over R-
methodol (Figure 5.5a). Given a shorter tether length for the amine group, Ac-
OrnLVFFAL-NH2 breaks the methodol more quickly than the Ac-KLVFFAL-NH2 does, 
consistent with its higher initial rate indicated in Figure 5.2. 
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The aldehyde product rebinds to both of the Ac-KLVFFAL-NH2 and Ac-
OrnLVFFAL-NH2 tubes. After eight hours of reaction, around 10 μM of methodol is 
reacted with Ac-KLVFFAL-NH2 tubes (Figure 5.5a), while only 6 μM of the aldehyde 
product is detected (Figure 5.5b). For Ac-OrnLVFFAL-NH2 tubes, they cleave around 35 
μM methodol but only 15 μM aldehyde product is detected, a difference of 20 M 
aldehyde product. As the aldehyde product shows fluorescence when it is dissolved in the 
solution but not in the binding pocket, the inconsistency between the substrate and 
product concentration implies that the aldehyde may rebind onto the tube surface. The 
product-rebinding behavior is detected in Figure 5.5b as well: before the methodol 
solution is mixed with the Ac-KLVFFAL-NH2 assemblies, it contains 2.5 μM of initial 
fluorescent aldehyde, the unreacted reagent after methodol synthesis. However, the 
aldehyde concentration drops to ~2 μM immediately after the mixture, which indicates 
the instant binding between the tubes and the aldehyde upon mixing.  
 To clarify the catalytic kinetics, the binding site concentration is required. Unlike 
protein enzymes, whose concentration may be directly derived from the protein 
concentration, here the binding site concentration of the tubes remains to be determined. 
Not all primary amine groups are capable of methodol cleavage; half of the amine groups 
are buried in the bi-layer structure of the peptide tubes [185], and the concentration of the 
active groups on the tube surface remains to be determined. To experimentally determine 
the number of peptides per binding site, 300 μM assembled Ac-KLVFFAL-NH2 peptides 
are titrated with 1-(6-methoxy-2-naphthalenyl)-1,3-butanedione. 1-(6-methoxy-2-
naphthalenyl)-1,3-butanedione has a similar size as the methodol substrate, binds onto the 
tube surface to form an enaminone, but does not undergo further cleavage (Figure 5.6). 
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The titration analysis shows that at least four peptides are needed to form a binding site 
(Figure 5.7) for 1-(6-methoxy-2-naphthalenyl)-1,3-butanedione.  
 
Figure 5.6  The binding step between the amine group on the lysine residue and 1-
(6-methoxy-2-naphthalenyl)-1,3-butanedione [188].  
 
Figure 5.7  Titrating 300 µM Ac-KLVFFAL-NH2 with 1-(6-methoxy-2-
naphthalenyl)-1,3-butanedione to determine the number of peptides per binding 
site. Enaminone formation upon addition of 1-(6-methoxy-2-naphthalenyl)-1,3-
butanedione to 300µM Ac-KLVFFAL-NH2 monitored by UV absorbance at 350 nm. 
When the amine groups on the tube surface is saturated with 1-(6-methoxy-2-
naphthalenyl)-1,3-butanedione and form enaminone as indicated in Figure 5.6, the 
enaminone concentration is about 76 μM. This suggests that the tube requires 
around 4 peptides (300 μM /76 μM) to form a binding site. Image adapted from Ref. 
[186] with permission. 
 To resolve the size of an active binding site, to verify the product-rebinding 
mechanism, and to investigate the enantioselectivity, the Michaelis-Menten mechanism is 
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modified for a bi-substrate system with product-rebinding to fit the experimental data. 
Retro-aldol kinetics is fit to this minimal model that contains the following steps (Figure 
5.8):  
(1) Equilibria between the methodol (S- and R-substrates) on the tube surface (E).  
(2) Carbon-carbon bond cleavage. 
(3) Product (P1 for aldehyde and P2 for acetone) release. 
(4) Equilibrium between the product, 6-amino-2-naphthaldehyde (P1), and tube surface.  
 
Figure 5.8  The modified Michaelis-Menten mechanism for retro-aldol reaction. E 
is binding site, S is S-methodol, ES is the bound complex, P1 is 6-methoxy-2-
naphthaldehyde, P2 is acetone, R is R-methodol, ER is the bound complex, and EP1 
is the enzyme-6-methoxy-2-naphthaldehyde complex.  
 The methodol consumption and aldehyde production are used to evaluate the 
parameters of the model in Figure 5.8. The parameter optimization is carried out by 
minimizing the sum of square error (SSE) between the calculated and experimental 
values, and the SSE is normalized for the number of data points and the scale of the 
measurements [135]. Latin Hypercube sampling [136] is used to sample 500 various 
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initial guesses for the kinetic parameters. The optimization procedure was carried out 
with the fmincon function in MATLAB 2012a (Mathwork, Inc).  
 The modified Michaelis-Menten mechanism is able to describe the reaction 
progress well (Figure 5.9), with eight peptides per binding sites for Ac-OrnLVFFAL-NH2 
and nine for Ac-KLVFFAL-NH2 tubes (Figure 5.10). Also, adjusting the amine position 
does not alter the tubes’ reactive mechanism, as Ac-OrnKLVFFAL-NH2 tubes follow the 
same reactions as the Ac-KLVFFAL-NH2 tubes, but with different rate constants. The 
optimal parameter sets (Table 5.1) for both tubes suggest that the binding affinity for the 
R-methodol is stronger than that for the S-methodol (KdR < KdS). However, the S-
methodol is consumed more quickly because it has a stronger chemical activity (kcatS > 
kcatR). When the number of binding site is abundant, the R-methodol cannot take the 
advantage of its better binding affinity, and thus S-methodol is preferred by the tubes for 
kinetic reasons.  
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Figure 5.9  The fits to the progress of retro-aldol reaction for methodol with Ac-
KLVFFAL-NH2 and Ac-OrnLVFFAL-NH2 tubes. (a) Chiral HPLC of 500 µM 
peptide and 76.7 µM racemic methodol. (b) Naphthaldehyde fluorescence of 500 µM 
peptides with 76.7 M racemic methodol. 
 
Figure 5.10  Normalized sum of square error (SSE) for R- and S-methodol 
consumption on Ac-KLVFFAL-NH2 (red) and Ac-(Orn)LVFFAL-NH2 (black) 
assemblies. Methodol consumption and production 6-amino-2-naphthaldehyde in 
Figure 5.5 are fit to the model in Figure 5.8 as a function of the number of peptides 
per binding site.  
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Table 5.1  The parameters of the best fits of Ac-KLVFFAL-NH2 and Ac-
OrnLVFFAL-NH2 tubes. The confidence intervals of those parameters are at 
the 95% confidence level.  
Parameter Ac-KLVFFAL-NH2 Ac-OrnLVFFAL-NH2 
kforR (s-1 M-1) 4.63 ± 4.73 × 10-5 2.09 ± 0.85 × 10-4 
kforS (s-1 M-1) 6.19 ± 15.7 × 10-6 4.92 ± 0.82 × 10-5 
kcatR (s-1) 3.46 ± 1.17 × 10-6  1.87 ± 0.06 × 10-5  
kcatS (s-1) 4.31 ± 1.57 × 10-5 1.48 ± 0.08 × 10-4 
ka (s-1 M-1) 2.67 ± 1.97 × 10-5 2.66 ± 0.68 × 10-4 
KdR (M) 2.44 ± 317 × 10-3 4.54 ± 2.95 × 10-2 
KdS (M) 3.18 ± 2.34 × 102 1.55 ± 1.56 × 100 
Kd (M) 5.83 ± 3.83 × 10-1 9.93 ± 1.47 × 10-1 
The R- and S- methodol has different binding and chemical propensities, which 
suggests the invertible enantioselectivity with different methodol/peptide ratio. The 
peptide tubes break S-methodol more quickly when the number of binding sites is not 
limited, due to its stronger chemical reactivity. When binding sites are scarce, the R-
methodol would be enantioselectively consumed as it has a stronger binding affinity and 
would occupy most of the binding sites; this hinders the binding of the S-methodol and 
the following chemical steps. Simulation shows that both tubes undergo such invertible 
enantioselectivity when the catalyst load is limited (Figure 5.11), which is defined as the 
ratio of the binding site concentration over the substrate concentration: 
  [binding site]Catalyst load = 
[substrate]
  (5.1) 











  (5.2) 
where Rc and Sc are the concentration of consumed R- and S-methodol. 
 
Figure 5.11  The invertible enantioselectivity of the Ac-KLVFFAL-NH2 and the 
Ac-OrnLVFFAL-NH2 tubes. Reaction time is eight hours and the parameter sets in 
Table 5.1 are used. The two data points represent the experimental results from 
Figure 5.5a. 
 Different combinations of methodol/peptide concentrations are applied 
experimentally to verify the hypothesis about the invertible enantioselectivity. The 
catalyst load is decreased for all conditions to test whether the tubes enantioselectively 
cleave the R-methodol; however, the S-methodol is enantioselectively preferred under all 
conditions tested here. Although the new data sets do not support the hypothesis, the joint 
fits of these data sets provide more insight about the properties of the catalytic peptide 
assemblies. 
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 Joint fits are carried out with the modified Michaelis-Menten mechanism (Figure 
5.8) for the extended data sets as a function of numbers of peptides per binding site. With 
the new methodol consumption and aldehyde generation data, the mechanistic model in 
Figure 5.8 suggests the number of peptides per binding sites equal to 6 (Figure 5.12). The 
normalized SSE shows similar trends for both the Ac-KLVFFAL-NH2 and Ac-
OrnLVFFAL-NH2 assemblies, with both having the lowest at six. This number is slightly 
greater than the experimentally determined value, which is four (Figure 5.7). The size 
difference in the calculated results and the experimental value indicates that not all 
binding sites are active for retrol-aldol reaction; the methodol may need to bind into the 
binding pocket with some specific relative positions with the amine group to trigger 
retro-aldol reaction.  
 
Figure 5.12  Normalized sum of square error (SSE) of the joint fits for R- and S-
methodol consumption on Ac-KLVFFAL-NH2 (red) and Ac-OrnLVFFAL-NH2 
(black) assemblies. 
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With six peptides per binding site, the modified Michaelis-Menten mechanism fits 
the kinetics well for both Ac-KLVFFAL-NH2 (Figure 5.13) and Ac-OrnLVFFAL-NH2 
(Figure 5.14) catalyzed substrate consumption and product accumulation. For the first 8 
hours given 500 μM peptides and 80 μM substrate, the fits show that the binding step, the 
chemical steps and the product-rebinding step are essential. The same parameters sets 
(Table 5.2) also fit the other conditions with different peptide and substrate concentration 
as a joint fit. As shown in Figure 5.13c, d and Figure 5.14c, d, the joint model fits follow 
the decrease of R- and S- methodol concentrations with doubled substrate concentration 
(160 μM) for up to 128 hours with two peptide concentrations (500 and 300 μM). Even 
though the catalyst load is decreased, the enantioselectivity of both tubes does not change 
as predicted in Figure 5.11, and the tubes still break S-methodol more quickly. Also with 
the joint fits, both the Ac-KLVFFAL-NH2 and the Ac-OrnLVFFAL-NH2 tubes bind R- 
and S-methodol without preference, given the close dissociation constants (KdR and KdS) 
in Table 5.2. Meanwhile, both type of tubes have a stronger chemical activity for the S-
methodol over the R-methodol (kcatS > kcatR); as both the two types of tubes have close 
binding affinity for R- and S-methodol, but break S-methodol more quickly, the 
enantioselectivity is not invertible by varying the catalyst load . 
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Figure 5.13  Best fits of Ac-KLVFFAL-NH2 retro-aldol catalysis with 6 peptides 
per binding site. (a) Chiral HPLC of 500 µM peptide and 76.7 µM racemic 
methodol. (b) Naphthaldehyde fluorescence of 500 µM peptides with 76.7 M 
racemic methodol (green), 79.2 M R-enriched methodol (black) and 79.1 M S-
enriched methodol (red). (c) Chiral HPLC of 500 µM peptide and 155.3 µM racemic 
methodol. (d) Chiral HPLC of 300 µM peptide and 155.4 µM racemic methodol.  
Solid lines are best fits with Figure 5.8. (a) Initial concentrations are: [E] = 83.3 μM, 
[S] = 38.3 μM, [R] = 38.5 μM, [P1] = 3.1 μM. (b) The initial concentrations of the 
racemic solution are: [E] = 83.3 μM, [S] = 38.3 μM, [R] = 38.5 μM, [P1] = 3.1 μM. 
The initial concentrations of the R-enriched substrate are: [E] = 83.3 μM, [S] = 11.9 
μM, [R] = 67.3 μM, [P1] = 0.77 μM. The initial concentrations of the S-enriched 
substrate are: [E] = 83.3 μM, [S] = 67.2 μM, [R] = 11.9 μM, [P1] = 0.95 μM. (c) The 
initial concentrations are: [E] = 83.3 μM, [S] = 77.0 μM, [R] = 78.4 μM, [P1] = 4.6 
μM. (d) The initial concentrations are: [E] = 50 μM, [S] = 77.0 μM, [R] = 78.4 μM, 




Figure 5.14  Best fits of Ac-OrnLVFFAL-NH2 retro-aldol catalysis with 6  peptides 
per binding site. (a) Chiral HPLC of 500 µM peptide and 76.7 µM racemic 
methodol. (b) Naphthaldehyde fluorescence of 500 µM peptides with 76.7 M 
racemic methodol (green), 79.2 M R-enriched methodol (black) and 79.1 M S-
enriched methodol (red). (c) Chiral HPLC of 500 µM peptide and 155.3 µM racemic 
methodol. (d) Chiral HPLC of 300 µM peptide and 155.4 µM racemic methodol.  
Solid lines are best fits from Figure 5.8 with (a) initial concentrations [E] = 83.3 μM, 
[S] = 38.3 μM, [R] = 38.5 μM, [P1] = 3.1 μM. (b) Initial concentrations of the racemic 
solution (green) [E] = 83.3 μM, [S] = 38.3 μM, [R] = 38.5 μM, [P1] = 3.1 μM, for  R-
enriched substrate (black) [E] = 83.3 μM, [S] = 11.9 μM, [R] = 67.3 μM, [P1] = 0.77 
μM and initial concentrations of the S-enriched substrate (red) [E] = 83.3 μM, [S] = 
67.2 μM, [R] = 11.9 μM, [P1] = 0.95 μM. (c) The initial concentrations are: [E] = 83.3 
μM, [S] = 77.0 μM, [R] = 78.4 μM, [P1] = 4.6 μM. (d) The initial concentrations are: 
[E] = 50 μM, [S] = 77.0 μM, [R] = 78.4 μM, [P1] = 4.6 μM. 
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Table 5.2  The optimal parameter sets for the joint fits of Ac-KLVFFAL-NH2 and 
Ac-OrnLVFFAL-NH2 tubes. The confidence intervals of those parameters are at 
the 95% confidence level. Kd for both tubes are acquired independently by titrating 
the tubes with the 6-amino-2-naphthaldehyde. 
Parameter Ac-KLVFFAL-NH2 Ac-OrnLVFFAL-NH2 
kforR (s-1 M-1) 3.98 ± 5.60 × 10-5 9.94 ± 1.62 × 10-6 
kforS (s-1 M-1) 9.18 ± 45.0 × 10-4 1.17 ± 0.25 × 10-4 
kcatR (s-1) 4.08 ± 1.26 × 10-5  6.00 ± 0.69 × 10-5  
kcatS (s-1) 6.20 ± 2.39 × 10-5 1.90 ± 0.35 × 10-4 
ka (s-1 M-1) 1.60 ± 0.07 × 10-5 7.47 ± 0.20 × 10-5 
KdR (M) 7.02 ± 3.05 × 101 1.21 ± 0.35 × 101 
KdS (M) 7.96 ± 4.33 × 101 2.51 ± 0.86 × 101 
Kd (M) 5.91 × 101 6.49 × 101 
 
 
Figure 5.15  The prediction of enantioselectivity of the Ac-KLVFFAL-NH2 and the 
Ac-OrnLVFFAL-NH2 tubes. Reaction time is eight hours and the parameter sets in 
Table 5.2 are used. The data points represent the experimental results from Figure 
5.13 and Figure 5.14.  
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The joint fits also reveal the physical properties of the peptide tubes. The fitting 
results follow the long-term data well with the same mechanism (Figure 5.8) and the 
same parameter set (Table 5.2). This suggests that the tubes are stable, the number of 
binding sites remains constant, and the catalytic nature of these binding pockets does not 
change during the catalytic reaction. The joint fits also suggest that the model is capable 
describing the data from different substrate and peptide concentration, and the 
mechanism remain the same even though the substrate and the peptide assemblies are 
mixed in different ratio.  
To compare the catalytic efficiency between different catalysts, the constants 
kcat/KM in the Michaelis-Menten kinetics (equation 5.3) are often used [191]: 








  (5.3) 
where P is the product, [E]tot is the total enzyme concentration, and [S]l is the substrate 
concentration. However, our peptide-methodol system does not satisfy the assumption to 
obtain equation 5.3. Although the rapid equilibration predicted by our simulations 
satisfies the basic quasi-steady-state assumption of Michaelis-Menten kinetics, our model 
does not follow kcat/KM calculations as [ER] and [ES] do not remain constant due to the 
limited substrate solubility. In addition to limitations of substrate solubility, product 
binding also makes the kinetics deviate from Michaelis-Menten kinetics early in the 
initial rates. Thus, equation 5.3 cannot be directly applied to the peptide tubes and kcat/KM 
calculated from this mechanism for our system will not accurately reflect its catalyst 
efficiency.  
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The enantioselectivity of the peptide assemblies is clarified with modeling 
simulation and discrimination. To test either the binding or the chemical step has a 
stronger impact to the enantioselectivity, parameter estimation for the modified 
Michaelis-Menten model (Figure 5.8) is carried out with restriction of equal chemical 
step constants (kcatR = kcatS) or equal substrate dissociation constants (KdR = KdS) for both 
Ac-KLVFFAL-NH2 (Table 5.3) and Ac-OrnLVFFAL-NH2 (Table 5.4) tubes. The 
goodness of fits for these restricted models is then compared to the original model by the 
Akaike information criterion (AIC) [192, 193] and the Akaike weight [129], as 
mentioned in Chapter 2. Here, AIC (equation 5.4) is used instead of AICc (equation 2.1) 




 , where Nd is the number of data points and Np is 
the number of parameters.) [194]. AIC measures the consistency of the models upon the 
data by rewarding the model with the less SSE or the less number of parameters, and is 
calculated based on: 
 







  (5.4) 
where SSE is the sum of squares error. The Akaike weight, on the other hand, indicates 
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where NM is the total number of models for comparison and  AICi  is the difference 
between the AIC of model i and the minimal AIC from the model set.  
 As shown in Table 5.3 and Table 5.4, the original model has the lowest AIC value 
and the greatest Akaike weight, most consistent with unequal dissociation constants and 
chemical steps. This suggests that the original model is not overfitting the data. However, 
the restriction on the chemical step constants (kcatR = kcatS) has a greater SSE than the 
dissociation constants for both tubes; this suggests that the chemical step has a stronger 
impact on the enantioselective consumption for both peptide assemblies. Therefore the 
nanotubes show a stronger binding affinity toward R-methodol, but still cleave S-
methodol selectively. 
Table 5.3  AIC analysis of the best fits for the modified Michaelis-Menten model 
for Ac-KLVFFAL-NH2 tubes. Nd is the number of data points, and Np is the number 
of parameters. 
Model Nd SSE Np AIC Akaike weight (%) 
Original 793 7.94 × 101 7 -1810.80 92.83 
kcatR = kcatS 793 2.00 × 102 6 -1079.94 0.00 
KdR = KdS 793 8.01 × 101 6 -1805.68 7.17 
  
Table 5.4  AIC analysis of the best fits for the modified Michaelis-Menten model 
for Ac-OrnLVFFAL-NH2 tubes. Nd is the number of data points, and Np is the 
number of parameters. 
Model Nd SSE Np AIC Akaike weight (%) 
No restriction 793 2.83 × 101 7 -2629.40 100.00 
kcatR = kcatS 793 1.07 × 102 6 -1573.16 0.00 
KdR = KdS 793 4.07 × 101 6 -2343.13 0.00 
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5.3 Conclusion 
In this chapter, the catalytic ability of the peptide assemblies is demonstrated and 
analyzed, which are able to cleave the methodol substrate. Among all the peptide 
assemblies tested, both Ac-KLVFFAL-NH2 and Ac-OrnLVFFAL-NH2 peptides show 
capability to catalyze the enantioselective chemical reaction with significant stability. 
As shown with the modeling results, these catalytic assemblies cleave the substrate 
by following the Michaelis-Menten mechanism with a product-rebinding step. The 
modeling and simulation clarify the number of peptides required for an active binding 
site, the critical step for enantioselectivity, and the stability of the tubes. Both type of the 
peptide tubes follow the same mechanism but with different rates, indicating that the 
catalytic efficiency may be systematically and rationally adjusted without altering the 
overall catalytic nature. 
5.4 Methods 
5.4.1 Synthesis of Methodol 
Racemic 4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone is synthesized based on Ref. 
[181, 195] via condensation of acetone with 6-methoxy-2-napthaldehyde.  Acetone (196 
μL, 2.50eq) in tetrahydrofuran (THF) is gently added into a freshly prepared solution of 
lithium diisopropylamide (LDA) under −78°C. The mixture is stirred at this temperature 
for 30 min, and then 6-methoxy-2-naphthaldehyde (100 mg, 1.07 mmol) in 5 ml THF is 
gently added into the mixture within one minute. After it is stirred for another 30 minutes 
under −78°C, the reaction is quenched by saturated NH4Cl under room temperature. The 
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product is extracted with ethyl acetate and dried with MgSO4, and then flash purified 
with SiO2, ethyl acetate and hexane. 
 For R-methodol preparation, acetone (100 ml) is mixed with 6-methoxy-2-
naphthaldehyde (887 mg, 4.76 mmol) and L-proline (248 mg, 0.40eq), and stirred at 
room temperature for 5 hours. The mixture is then dried down under vacuum, re-
suspended in 40 ml vinyl acetate and treated with P.cepacia (1.32 g, 245 mg/mmol 
substrate), a 4Å molecular sieve was added. The mixture is placed at room temperature 
under N2 protection overnight, and the reaction crude is filtered and applied to flash 
column.  
 For S-methodol, 6-methoxy-2-naphthaldehyde (500 mg, 2.68 mmol) and D-
proline (124 mg, 0.40eq) are mixed with 60 ml acetone at room temperature for three 
hours. After the solids are removed by filtration, the filtrate is dried down under vacuum 
and applied to flash column directly. 
5.4.2 Synthesis of 1-(6-methoxy-2-naphthalenyl)-1,3-butanedione 
244 mg of 4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone is dissolved in 10 mL 
chloroform, and the solution is incubated with 1.5 equivalents of Dess-Martin 
periodinane in chloroform at room temperature overnight. The product is purified by 
silica gel chromatography with hexanes and ethyl acetate.  
5.4.3 Preparation of Peptide Assembly Solution 
The peptides are synthesized using solid phase peptide synthesis, and the synthetic 
products are purified with high-performance liquid chromatography (HPLC), using a 
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water/acetonitrile gradient with 0.1% trifluoroacetic acid in a C-18 reverse phase column. 
After lyophilization, the purified peptide is stored at -20 oC for later use [21].  
To assemble the peptides, the peptides (2.5 mM) are dissolved in 40% acetonitrile 
(ACN) aqueous solvent with 0.1% trifluoroacetic acid (TFA). Dissolution is assisted by 
two minutes of continuous vortexing, followed by 15 minutes of sonication until solution 
becomes clear. The solution is placed under 4 °C for two weeks to allow the peptides to 
assemble.  
5.4.4 Transmission Electron Microscopy 
The morphologies of the assembled peptides are observed with transmission electron 
microscopy (TEM). The peptide solution is diluted for ten times, and then the diluted 
portion is loaded onto the copper grid for 1 min. The excess solution is wicked away with 
filter paper. The resulting grid is negatively stained with 2% uranyl acetate in water for 1-
2 minutes for fibers and 4-5 minutes for nanotubes before the stain solution is removed 
with filter paper. The grid is then stored in a vacuum desiccator overnight to remove the 
remaining liquid. TEM images are recorded with a Hitachi H-7500 transmission electron 
microscope. 
5.4.5 Molecular Dynamic Simulation 
Methodol docking onto the KLVFFAL tube surface is performed manually with energy 
minimization in Macromodel (Schrodinger, Inc. Portland, OR) [196].  To define the 
lysine accessibility across the tube surface, a one ns molecular dynamics (MD) run 
(Desmond) [197] at 300 K with SPC explicit water model [198] and the OPLS2005 all 
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atom force field [199] is carried out starting with eight peptides assembled with hydrogen 
bonding per laminate, with totally five laminates of KLVFFAL peptides in SPC water. 
Initial structures were allowed to relax for 100 ps before the run. Boundary conditions 
were set to create infinite H-bonded β-sheets and infinite β-sheet stacking.  
5.4.6 Retro-aldol Analysis 
The kinetics of retro-aldol reaction are followed by fluorescence for product 
concentration and HPLC for substrate concentration. Right before the kinetic 
measurements, the peptide assemblies are centrifuged under 13,800 × g for 60 minutes 
and then are re-suspended with distilled water. The peptide solution is buffered to pH 7.5 
with 50 mM phosphate and 300 mM NaCl, with 5% DMSO to enhance the solubility of 
methodol. After the methodol solution is mixed with the peptide solution, fluorescence 
measurements for the reaction mixture are conducted on a Synergy HT Multi-detection 
microplate reader.  Triplicate samples of 200 L are measured with excitation at 360 nm 
and fluorescence emission at 460 nm, and data are collected every 45 seconds, with the 
plates shaken for 20 revolutions per second.  
The enantioselectivity of the peptide assemblies is determined by chiral HPLC 
analysis using a Chiralpak AD-RH (Daicel) column. After the peptide solution is mixed 
with the substrate methodol, the remaining R- and S-methodol are separated and 
quantified with the chiral HPLC kinetically. The elution time points for R- and S-
methodol are 18.6 and 21.3 minutes, respectively, when the reaction mixture is eluted 
from HPLC isocratically with 40% ACN at a flow rate of 0.5 mL/min.  
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CHAPTER 6. CONCLUSION AND RECOMMENDATIONS 
6.1 Conclusion 
The main goal of this thesis is to provide a comprehensive study about building the 
peptide-based biomaterials. The crucial building blocks capable of assembly, the 
assembly pathway, and the catalytic function of the assemblies are analyzed 
experimentally and mathematically. The synthesis and selection of the building blocks 
are demonstrated via the dynamic combinatorial networks, which yields sequence-
defined peptide oligomers. Next, the assembly mechanism is simulated with a two-step 
nucleation model, and the model is experimentally tested with a pH-sensitive peptide, 
A(16-22); extension of this model for a polydisperse system provides insights about the 
physical and chemical phases. Given the structures studied, the catalytic function of the 
peptide nanotube assemblies is analyzed to reveal the underlying mechanism which 
selectively breaks the substrate. 
 The building blocks determine the properties of the assemblies. It is demonstrated 
in Chapter 2 that the peptide oligomers as the building blocks may be synthesized from a 
dynamic combinatorial network (DCN). Two DCNs are constructed with chemically 
modified peptides, NF-CHO and NFF-CHO. The two DCNs behave similarly and they 
undergo the same physical transitions. The metastable particle phase nucleate as the 
average oligomer length increases, and later the fibers nucleate inside these particles. The 
experiments reveal that the emergent physical phases cause the species redistribution, and 
the modeling simulation supports this interplay between the chemical and the physical 
phases. As both networks yield trimer with high fidelity, construction of the DCNs may 
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become a new way to synthesize sequence-defined oligomers, the building blocks for the 
mesoscale materials. 
 Next, to understand the multi-stage assembly pathway observed in the DCN, a 
peptide assembly model with two-step nucleation is constructed for a monodisperse 
system. It addresses that the final thermodynamic state of the solution is determined by 
the solubilities of the particles and the assemblies. The phase with a higher solubility will 
diminish while the other survives. However, this process may be kinetically hindered 
with slow particle growth and dissolution. The utility of the monodisperse model is tested 
experimentally with the assembly kinetics of the A(16-22) peptide. A(16-22) 
assembles more quickly as the acetonitrile concentration increases, and this trend is 
rationally explained by the model that the kinetics is limited when the peptide solubility 
for the particles decreases. Next, the addition of the peptide oligomerization makes the 
model capable of simulating the polydisperse systems with reversible oligomerization. 
For the polydisperse model, the equilibrium of the chemical distribution (oligomer 
concentrations) and the physical distribution (overall oligomer mass in different physical 
phases) may be achieved independently. This suggests that once the desired chemical or 
physical distribution is achieved, the system may be harvested before the other phase 
become stationary.  
 The reaction pathway and the morphological selection are further investigated 
with the pH sensitive A(16-22). The pH-dependent A(16-22) assembly reveals the 
importance of the environments for assembly nucleation and growth. As A(16-22) 
assembles with two-step nucleation, the assemblies nucleate in the particle while grow in 
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the aqueous solution. At both acidic and neutral pH, A(16-22) assembles into the 
metastable ribbons in the particles. The same intermediate products from both pH 
conditions suggest that the particles, where the ribbons nucleate, are similar and pH-
independent. The metastable ribbons diminish after the other thermodynamically stable 
morphologies arise in the solvent, the propagation environment. 
 Finally, the catalytic function of the peptide assemblies is analyzed. The Ac-
KLVFFAL-NH2 and the Ac-OrnLVFFAL-NH2 nanotubes catalyze a retro-aldol reaction 
on the methodol substrate, and the catalytic reaction progress is fitted by a modified 
Michaelis-Menten mechanism. The result suggests similar size of the binding pocket for 
both peptides. The consistent parameter set suggests that the peptide nanotubes are stable 
throughout the entire reaction time, and their chemical activity does not decay during the 
reaction. The enantioselectivity for the methodol substrate may come from the chemical 
selectivity of the peptide nanotubes, but not from the different binding activity, based on 
the analysis.  
 To fully understand and engineer the materials, their building block, construction 
pathway, and functions are all essential and should not be studied separately from each 
other. The above work provides a comprehensive board view about studying the 
construction of functional biomaterial by analyzing the building block, the assembly 
mechanism, and the catalytic function of the peptide assemblies. This achievement brings 
a broader view for studies to follow, which may make the peptide-based materials more 
viable and accessible. 
6.2 Recommendations 
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6.2.1 Construction of DCNs with -helical Structure 
In the human body, collagen is the most abundant protein, which is constituted 
mainly by proline (P) and glycine (G). Each chain in collagen is about 1400 amino acids 
long, and three chains would coil together into a tight triple helix. Glycine-proline-X is a 
common repeating sequence in collagen, which results in the helical structures with 
intramolecular hydrogen bonds. 
By mimicking the collagen structure, the NGP-CHO monomer may be used to 
achieve the -helical structure to template the growth of longer oligomers via DCN. As 
the NGP-CHO monomer undergoes oligomerization, the oligomers may have propensity 
to assemble into the triple-helix structure, as the [NGP]n sequence is similar to the 
glycine-proline-X sequence observed in collagen. The end of the helical structure then 
may propagate by the incorporating more NGP-CHO molecules, and thus longer 
oligomers within the DCN may be synthesized. 
6.2.2 NF-CHO Tetramer Formation from Templating 
In the DCNs investigated in the thesis, both the NF-CHO and NFF-CHO trimers 
assemble into nanofibers with the -sheet structure. As a result, the longest stable product 
detected in these two networks is trimer, while the other longer oligomers are not 
identified. The trimer assemblies may be kinetic products, and they predominate before 
the assemblies of other longer oligomers nucleate. 
 To test if the NF-CHO molecules may oligomerize into tetramer (4-mer), the NF-
CHO network may be seeded with the assemblies of peptide NFNFNFNF, which might 
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template the formation of tetramer and thus make the tetramer assemblies predominate, 
instead of the trimer assemblies. Given the tetramer assemblies built from seeding, the 
trimer assemblies are shown to be kinetic products only, while the tetramers are more 
thermodynamically stable.  
 
Figure 6.1 The templated formation of the NF-CHO tetramer via the (NF)4 
assemblies. 
 
6.2.3 Peptide Assembly via Two-step Nucleation with Different Morphologies 
In this thesis, it is simulated that the peptides assemble into linear fibers from spherical 
particles. The model may be modified to fit other systems with different morphologies. 
For example, -lactoglobulin has an amorphous metastable phase before its crystal arise 
[64, 90]; the bis-FF dipeptide fibers are nucleated inside the particles, but those fibers 
further transform into tubes [71]. It requires different rate equations to express these 
transition from the metastable phase to the final phase, and the nucleation mechanism 
may also be different from what is discussed in this thesis. Addition of these different 
morphological combinations may make the model more robust to simulate the multi-step 
nucleation process. 





The ordered structures of the Ac-KLVFFAL-NH2 and the Ac-OrnLVFFAL-NH2 provide 
catalytic binding sites for a retro-aldol reaction. With the primary amine group on the 
tube surface, the peptide tubes are able to catalyse the retro-aldol reaction and cleave the 
methodol substrate. 
As the primary amine group on the assembly surface is crucial for catalysis, the 
DCN building blocks may be designed as Ac-KF-CHO and NFL-NH2 to access catalytic 
function. Ac-KLVF-CHO and NAL-NH2 may dimerize into Ac-KLVFNAL-NH2 with the 
reversible acetal linkage. If the dimers assemble into ordered structures similar to the Ac-
KLVFFAL-NH2 tubes, they may be able to catalyse the retro-aldol reaction, and become  
a DCN product from the DCN with emergent catalytic function. 
6.2.5 Transition from Out-of-register Ribbons to In-register Fibers 
When A(16-22) is incubated at neutral pH, it assemble into metastable out-of-register 
ribbons, which then diminish and transition into the stable fiber with in-register -sheet 
structure. However, the nucleation mechanism of the in-register structure remains to be 
clarified. The hypothesis for the place of fiber nucleation includes: 1) inside the particle, 
and 2) on the ribbon surface. If the fiber nucleates inside the particles, NMR may be used 
to probe the in-register structure in the particle. If the fiber nucleate on the ribbon surface 
with a secondary nucleation process, the out-of-register ribbon from Ac-KLVFFAL-NH2 
may be seeded into the A(16-22), which should make the fibers nucleate more quickly 
given more nucleation sites. The results of these experiments may help to clarify the 
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